Exhibit B

U.S. Patent 5,712,155
and
Pending Reissue Application for Patent Based Thereon

LAW OFFICES
SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20037-3202
TELEPHONE (202) 293-7060
FACSIMILE (202) 293-7860

CALIFORNIA OFFICE
1010 EL CAMINO REAL
MENLO PARK, CA 94025
TELEPHONE (650) 325-5800
FACSIMILE (650) 325-6606

JAPAN OFFICE
TOEI NISHI SHIMBASHI BLDG. 4F
13-5 NISHI SHIMBASHI 1-CHOME
MINATO-KU, TOKYO 105, JAPAN
TELEPHONE (03) 3503-3760
FACSIMILE (03) 3503-3756

August 31, 1998

BOX PATENT APPLICATION
Assistant Commissioner
for Patents
Washington, D.C. 20231

Re: Reissue Application of
Craig A. SMITH, Raymond G. GOODWIN
and **M. Patricia BECKMANN** entitled
"DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS"
Our Ref: **A-7210**

Dear Sir:

This is a request for filing a Reissue Application of U.S. Patent No. 5,712,155, which issued on January 27, 1998, by Craig A. SMITH, Raymond G. GOODWIN and M. Patricia BECKMANN entitled "DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS".[1/]

This application is being filed under 37 C.F.R. § 1.171. Enclosed is the specification, claims, Abstract pursuant to 37 C.F.R. § 1.173, six (6) sheets of drawings, an executed Reissue Declaration and Power of Attorney and an Information Disclosure Statement.

Consent of the Assignee to Reissue Pursuant to 37 C.F.R. § 1.172(a), and Offer to Surrender Letters Patent Pursuant to 37 C.F.R. § 1.178, are also submitted herewith.

1/ A Certificate of Correction for U.S. Patent 5,712,155 was issued August 18, 1998, to correct minor printing errors.

The application underlying U.S. Patent No. 5,712,155 was assigned to Examiner Daryl Basham in Group Art Unit 1646.

The Government filing fee is calculated as follows:

Total Claims.....	271	- 20 =	251	x $22 =	$5,522.00
Independent Claims..	17	- 3 =	14	x $82 =	$1,148.00
Base Fee					$ 790.00
Multiple Dependent Fee ($ 270.00).....					$ 270.00
TOTAL FILING FEE.....					$7,730.00

The Assistant Commissioner is hereby authorized to charge Applicants' Deposit Account No. 19-4880 in the amount of $ 7,730.00 for the government fee.

The Assistant Commissioner is also hereby directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880.

The Assistant Commissioner is also hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17, and any petitions for extension of time under 37 C.F.R. § 1.136, which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Respectfully submitted,

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC

Gordon Kit
Registration No. 30,764

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

CRAIG A. SMITH et al

Reissue Application of:
U.S. Patent 5,712,155

Group Art Unit: **1646**

Examiner: **Basham, D.**

Issued: **January 27, 1998**

Reissue Application Filed : **August 31, 1998**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

CONSENT OF THE ASSIGNEE TO REISSUE PURSUANT TO 37 C.F.R. § 1.171(a)

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

Immunex Corporation is the assignee, i.e., owner, of the entire right, title and interest of the technology disclosed and claimed in Smith et al, U.S. Patent 5,712,155, which issued on January 27, 1998, as evidenced by the Assignment recorded in Parent U.S. Patent Application Serial No. 07/523,635, at Reel 5325, Frame 0315.

Immunex Corporation hereby certifies that the above-mentioned Assignment has been reviewed and to the best of Immunex Corporation's knowledge and belief, title is in Immunex Corporation which is seeking to take this action.

Immunex Corporation hereby consents to the filing of a reissue application of Smith et al, U.S. Patent 5,712,155.

CONSENT OF THE ASSIGNEE TO REISSUE
PURSUANT TO 37 C.F.R. § 1.171(a)
U.S. Patent No. 5,712,155

By virtue of my position at Immunex Corporation, I am authorized to sign this written consent on behalf of the assignee, i.e., Immunex Corporation, of Smith et al, U.S. Patent 5,712,155.

Scott G. Hallquist
Senior Vice President
General Counsel
Immunex Corporation

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

CRAIG A. SMITH et al

Reissue Application of:
U.S. Patent 5,712,155

Group Art Unit: **1646**

Examiner: **Basham, D.**

Issued: **January 27, 1998**

Reissue Application Filed : **August 31, 1998**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

OFFER TO SURRENDER LETTERS PATENT PURSUANT TO 37 C.F.R. § 1.178

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

Immunex Corporation is the assignees, i.e., owner, of the entire right, title and interest of the technology disclosed and claimed in Smith et al, U.S. Patent 5,712,155, which issued on January 27, 1998, as evidenced by the Assignments recorded in Parent U.S. Patent Application Serial No. 07/523,635, on at Reel 5325, Frame 0315.

Immunex Corporation hereby certifies that the above-mentioned Assignment has been reviewed and to the best of Immunex Corporation's knowledge and belief, title is in Immunex Corporation which is seeking to take this action.

OFFER TO SURRENDER LETTERS PATENT
PURSUANT TO 37 C.F.R. § 1.178
U.S. Patent 5,712,155

Immunex Corporation hereby offers to surrender the original Letters Patent U.S. Patent 5,712,155 to the United States Patent and Trademark Office.

By virtue of my position at Immunex Corporation, I am authorized to sign this offer to surrender on behalf of the assignee, i.e., Immunex Corporation, of Smith et al, U.S. Patent 5,712,155.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of U.S. Patent 5,712,155.

Scott G. Hallquist
Senior Vice President
General Counsel
Immunex Corporation

SOLE/JOINT

REISSUE DECLARATION AND POWER OF ATTORNEY

As below named inventors, we hereby declare that our residence, post office address and citizenship are as stated below next to our name: that we verily believe we are the original, first and joint inventors of the subject matter which is described and claimed in U.S. Patent 5,712,155, granted January 27, 1998, and for which a reissue patent is sought on the invention entitled:

DNA ENCODING TUMOR NECROSIS
FACTOR-α AND -β RECEPTORS

the specification of which is attached hereto.

We have reviewed and understand the contents of the above-identified specification, including the claims; that we acknowledge our duty to disclose information of which we are aware which is material to the patentability of this application under 37 C.F.R. 1.56. We verily believe the original patent to be wholly or partially inoperative or invalid by reason of the patentees claiming less than we had a right to claim, i.e., due to our Attorney's failure to appreciate the full scope of our invention, we did not initially claim a process for producing the protein capable of binding TNF (now sought in Reissue Claims 28-31, 42-45, 56-59, 70-73 and 84-87), and we did not claim the varied scope of DNA molecules, vectors and host cells (now sought in Reissue Claims 18-27, 32-41, 46-55, 60-69 and 74-83).

We hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any provisional application or foreign application(s) for patent or inventor's certificate listed below and have also identified on said list any foreign application for patent or inventor's certificate on this invention having a filing date before that of any foreign application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed (yes or no)

We hereby claim the benefit of Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, We acknowledge our duty to disclose any information material to the patentability of this application under 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
07/403,241	September 5, 1989	Abandoned
07/405,370	September 11, 1989	Abandoned
07/421,417	October 13, 1989	Abandoned
07/523,635	May 10, 1990	Patented (U.S. Patent 5,395,760)
08/346,555	November 29, 1994	Patented (U.S. Patent 5,712,155)

All errors corrected in this reissue application arose without any deception intention on the part of applicants.

We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Scott M. Daniels, Reg. No. 32,562; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; and Robert M. Masters, Reg. No. 35,603, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 8/28/98 First Inventor Craig (First Name) A. (Middle Initial) SMITH (Last Name)

Residence Seattle, WASHINGTON Signature Craig A. Smith

Post Office Address: 2405 5th West, Seattle, WASHINGTON 98119

Citizenship U.S.A.

Date 8/28/98 Second Inventor Raymond (First Name) G. (Middle Initial) GOODWIN (Last Name)

Residence Seattle, WASHINGTON Signature Raymond G. Goodwin

Post Office Address: 3322 8th Avenue West, Seattle, WASHINGTON 98119

Citizenship U.S.A.

Date 8/28/98 Third Inventor M. (First Name) Patricia (Middle Initial) BECKMANN (Last Name)

Residence Poulsbo, WASHINGTON Signature M. Patricia Beckmann

Post Office Address: 5454 Ragan Lane, Poulsbo, WASHINGTON 98370

Citizenship U.S.A.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

CRAIG A. SMITH et al

Reissue Application of: **U.S. Patent 5,712,155** Group Art Unit: **1646**

Issued: **January 27, 1998** Examiner: **Basham, D.**

Reissue Application Filed: **August 31, 1998**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 which the Examiner may deem relevant to the patentability of the claims of the above-identified application.

The listed documents were either cited by the Examiner or brought to the Examiner's attention by Applicants in Parent U.S. Patent No. 5,712,155; Grandparent U.S. Application Serial No. 07/523,635 (now U.S. Patent 5,395,760); Great Grandparent U.S. Application Serial No. 07/421,417; Great-Great Grandparent U.S. Application Serial No. 07/405,370; and Great-Great-Great Grandparent U.S. Application Serial No. 07/403,241.

Also, several additional references have been cited in related U.S. Application Serial No. 08/038,765, filed March 19, 1993; U.S.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98
Reissue of U.S. Patent No. 5,712,155

Application Serial No. 08/555,629, filed November 9, 1995; and U.S. Application Serial No. 08/953,268, filed October 17, 1997, which may be considered to be relevant to patentability of the claims of the above-identified application. Hence, no references are being provided herewith.

The present Information Disclosure Statement is being filed no later than three months from the application's reissue filing date and before the mailing date of the first Office Action on the merits, and therefore no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
(202) 293-7060

Date: August 31, 1998

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A-7210	SERIAL NO. Reissue of USP 5,715,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT CRAIG SMITH et al	
(Use several sheets if necessary)	FILING DATE August 31, 1998	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,447,851	09/05/95	Beutler et al			
		5,610,279	03/11/97	Brockhaus et al			
		5,116,964	05/26/92	Capon et al			
		5,605,690	02/25/97	Jacobs et al			
		5,155,027	10/13/93	Sledziewski et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		0,464,533	06/22/91	Europe				
		0,417,563	03/20/91	Europe				
	WO	89/02922	04/06/89	PCT				
	WO	91/08298	06/13/91	PCT				
		0,394,827	04/19/90	Euorpe				
		0,332,867	07/26/89	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

			Ashkenazi et al, *Proc. Natl. Acad. Sci., USA*, 88:10535-10539 (1991)
			Capon et al, *Nature*, 337:525-530 (1989)
			Evans et al, *J. Exp. Med.*, 180:2173-2179 (1994)
			Imamura et al, *J. Immunol.*, 139:2989-2992 (1987)
			Ishikura et al, *Blood*, 73:419-424 (1989)
			Jones et al, *Nature*, 338:225-228 (1989)
			Langer et al, *In: New Advances on Cytokines*, Eds. Romagnani et al, Raven Press, New York, pages 349-354 (1992)
			Lesslauer et al, *Eur. J. Immunol.*, 21:2883-2886 (1991)
			Loetscher et al, *J. Biol. Chem.*, 266(2):18324-18329 (1991)
			Mohler et al, *J. Immunol.*, 151:1548-1561 (1993)
			Peppel et al, *J. Cell. Biochem. Supp.*, 0(15 Part F):118 (1991)
			Peppel et al, *J. Exp. Med.*, 174:1483-1489 (1991)
			Rutka et al, *Int. J. Cancer Res.*, 41:573-582 (1988)
			Smith et al, *J. Biol. Chem.*, 262:6951-6954 (1987)
			Smith et al, *Science*, 248:1019-1023 (1990)

EXAMINER DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449 [6-4])

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A-7210	SERIAL NO. Reissue of USP 5,712,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT CRAIG SMITH et al	
	FILING DATE August 31, 1998	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,397,576	03/07/95	Smith et al			
		5,478,925	12/26/95	Wallach et al			
		4,935,233	06/19/90	Bell et al			
		5,712,155	01/27/98	Smith et al			
		5,696,095	12/09/97	Wallach et al			
		5,512,544	04/30/96	Wallach et al			
		4,677,054	06/23/87	Clark et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		0,418,014	03/20/91	Europe				
		2,220,122	11/08/89	United Kingdom				
		61-282,494	12/24/86	Japan			Yes	
	WO	90/11,355	11/15/90	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

			Dembic et al, *Cytokine*, 2:231-237 (1990)
			Kohno et al, *Proc. Natl. Acad. Sci., USA*, 87:8331-8335 (1990)
			Loetscher et al, *Cell*, 61:351-359 (1990)
			Nophar et al, *EMBO J.*, 9:3269-3278 (1990)
			Pennica et al, *Nature*, 312:724 (1984)
			Gray et al, *Nature*, 312:721 (1984)
			Baglioni et al, *J. Biol. Chem.*, 260:13395 (1985)
			Aggarwal et al, *Nature*, 318:665 (1985)
			Yoshie et al, *J. Biochem.*, 100:531 (1986)
			Israel et al, *Immunology Letters*, 12:217 (1986)
			Creasley et al, *Proc. Natl. Acad. Sci., USA*, 84:3293 (1987)
			Stauber et al, *J. Biol. Chem.*, 263(35):19098-19104 (1988)
			Aggarwal et al, *J. Biol. Chem.*, 262:10000 (1987)
			Tsujimoto et al, *J. Immun.*, 136:2441 (1987)
			Holtmann et al, *J. Immunol.*, 139:1161 (1987)
			Shalaby et al, *J. Leukocyte Biol.*, 41:196 (1987)

EXAMINER DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
(Form PTO-1449 [6-4])

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A-7210	SERIAL NO. Reissue of USP 5,712,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT CRAIG SMITH et al	
(Use several sheets if necessary)	FILING DATE August 31, 1998	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		0 4 2 2 3 3 9	07/17/90	Europe				
		0 3 0 8 3 7 8	03/22/89	Europe				
		3 9 8 3 2 7		Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

			Unglaub et al, *J. Exp. Med.*, 166:1788 (1987)
			Yonehara et al, *J. Exp. Med.*, 167:1511 (1988)
			Peetre et al, *Eur. J. Haematol.*, 41:414 (1988)
			Englemann et al, *J. Biol. Chem.*, 264:11974 (1989)
			Okayama et al, *Mol. Cell. Biol.*, 2:161 (1982)
			Okayama et al, *Mol. Cell. Biol.*, 3:280 (1983)
			Aruffo et al, *Proc. Natl. Acad. Sci., USA*, 84:8573
			Yamasaki et al, *Science*, 241:825 (1988)
			Sims et al, *Science*, 241:585 (1988)
			Tsujimoto et al, *Arch. Biochem. and Biophys.*, pages 563-568 (1986)
			Suggs et al, *PNAS*, 78:6613-6617 (1981)
			Kull et al, *PNAS*, 82:5756-5760 (1985)
			Goodman, *J. in Basic and Clinical Immunology*, pages 24-25, Lange Medical Publications, Los Altos, California (1982)
			Goodman, *J. in Basic and Clinical Immunology*, pages 101-108, 7th ed., (Sites et al, eds.), Appleton & Lange, Norwalk, CONN. (1991)

EXAMINER DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
(Form PTO-1449 [6-4])

TITLE

DNA Encoding Tumor Necrosis Factor-α and -β Receptors

CROSS-REFERENCE TO RELATED APPLICATION

This application is a Reissue of U.S. Patent No. 5,712,155, which issued from U.S. Application Serial No. 08/346,555, filed November 29, 1994; which is a Continuation of U.S. Application Serial No. 07/523,635, filed May 10, 1990, now U.S. Patent 5,395,760, which is a Continuation-In-Part of U.S. Application Serial No. 07/421,417, filed October 13, 1989[,]; now abandoned, which is a Continuation-In-Part of U.S. Application Serial No. 07/405,370, filed September 11, 1989, now abandoned, which is a Continuation-In-Part of U.S. Application Serial No. 07/403,241, filed September 5, 1989, now abandoned.

BACKGROUND OF THE INVENTION

The present invention relates generally to cytokine receptors and more specifically to tumor necrosis factor receptors.

Tumor necrosis factor-α (TNFα, also known as cachectin) and tumor necrosis factor-β (TNFβ, also known as lymphotoxin) are homologous mammalian endogenous secretory proteins capable of inducing a wide variety of effects on a large number of cell types. The great similarities in the structural and functional characteristics of these two cytokines have resulted in their collective description as "TNF." Complementary cDNA clones encoding TNFα (Pennica et al., *Nature 312*:724, 1984) and TNFβ (Gray et al., *Nature 312*:721, 1984) have been isolated, permitting further structural and biological characterization of TNF.

TNF proteins initiate their biological effect on cells by binding to specific TNF receptor (TNF-R) proteins expressed on the plasma membrane of a TNF-responsive cell. TNFα and TNFβ were first shown to bind to a common receptor on the human cervical carcinoma cell line ME-180 (Aggarwal et al., *Nature 318*:665, 1985). Estimates of the size

of the TNF-R determined by affinity labeling studies ranged from 54 to 175 kDa (Creasey et al, *Proc. Natl. Acad. Sci. USA 84*:3293, 1987; Stauber et al., *J. Biol. Chem. 263*:19098, 1988; Hohmann et al., *J. Biol. Chem. 264*:14927, 1989). Although the relationship between these TNF-Rs of different molecular mass is unclear, Hohmann et al. (*J. Biol. Chem. 264*:14927, 1989) reported that at least two different cell surface receptors for TNF exist on different cell types. These receptors have an apparent molecular mass of about 80 kDa and about 55-60 kDa, respectively. None of the above publications, however, reported the purification to homogeneity of cell surface TNF receptors.

In addition to cell surface receptors for TNF, soluble proteins from human urine capable of binding TNF have also been identified (Peetre et al., *Eur. J. Haematol. 41*:414, 1988; Seckinger et al., *J. Exp. Med. 167*:1511, 1988; Seckinger et al., *J. Biol. Chem. 264*:11966, 1989; UK Patent Application, Publ. No. 2 218 101 A to Seckinger et al.; Engelmann et al., *J. Biol. Chem. 264*:11974, 1989). The soluble urinary TNF binding protein disclosed by UK 2 218 101 A has a partial N-terminal amino acid sequence of Asp-Ser-Val-Cys-Pro-, which corresponds to the partial sequence disclosed later by Engelmann et al. (1989). The relationship of the above soluble urinary binding proteins was further elucidated after original parent application (U.S. Serial No. 07/403,241) of the present application was filed, when Engelmann et al. reported the identification and purification of a second distinct soluble urinary TNF binding protein having an N-terminal amino acid sequence of Val-Ala-Phe-Thr-Pro- (*J. Biol. Chem. 265*:1531, 1990). The two urinary proteins disclosed by the UK 2 218 101 A and the Engelmann et al. publications were shown to be immunochemically related to two apparently distinct cell surface proteins by the ability of antiserum against the binding proteins to inhibit TNF binding to certain cells.

More recently, two separate groups reported the molecular cloning and expression of a human 55 kDa TNF-R (Loetscher et al., *Cell 61*:351, 1990; Schall et al., *Cell 61*:361, 1990). The TNF-R of both groups has an N-terminal amino acid sequence which corresponds to the partial amino acid sequence of the urinary binding protein disclosed by UK 2 218 101 A, Engelmann et al. (1989) and Englelmann et al. (1990).

In order to elucidate the relationship of the multiple forms of TNF-R and soluble urinary TNF binding proteins, or to study the structural and biological characteristics of TNF-Rs and the role played by TNF-Rs in the responses of various cell populations to TNF or other cytokine stimulation, or to use TNF-Rs effectively in therapy, diagnosis, or assay, purified compositions of TNF-R are needed. Such compositions, however, are obtainable in practical yields only by cloning and expressing genes encoding the receptors using recombinant DNA technology. [Efforst] Efforts to purify the TNF-R molecule for use in biochemical analysis or to clone and express mammalian genes encoding TNF-R, however, have been impeded by lack of a suitable source of receptor protein or mRNA. Prior to the present invention, no cell lines were known to express high levels of TNF-R constitutively and continuously, which precluded purification of receptor for sequencing or construction of genetic libraries for cDNA cloning.

SUMMARY OF THE INVENTION

The present invention provides isolated TNF receptors and DNA sequences encoding mammalian tumor necrosis factor receptors (TNF-R), in particular, human TNF-Rs. Such DNA sequences include (a) cDNA clones having a nucleotide sequence derived from the coding region of a native TNF-R gene; (b) DNA sequences which are capable of hybridization to the cDNA clones of (a) under moderately stringent conditions and which encode biologically active TNF-R molecules; or (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R molecules. In particular, the present invention provides DNA sequences which encode soluble TNF receptors.

The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, recombinant TNF-R molecules produced using the recombinant expression vectors, and processes for producing the recombinant TNF-R molecules using the expression vectors.

The present invention also provides isolated or purified protein compositions comprising TNF-R, and, in particular, soluble forms of TNF-R.

The present invention also provides compositions for use in therapy, diagnosis, assay of TNF-R, or in raising antibodies to TNF-R, comprising effective quantities of soluble native or recombinant receptor proteins prepared according to the foregoing processes.

Because of the ability of TNF to specifically bind TNF receptors (TNF-Rs), purified TNF-R compositions will be useful in diagnostic assays for TNF, as well as in raising antibodies to TNF receptor for use in diagnosis and therapy. In addition, purified TNF receptor compositions may be used directly in therapy to bind or scavenge TNF, thereby providing a means for regulating the immune activities of this cytokine.

These and other aspects of the present invention will become evident upon reference to the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the coding region of various cDNAs encoding human and murine TNF-Rs. The leader sequence is hatched and the transmembrane region is solid.

Figures 2A-2B depict the partial cDNA sequence and derived amino acid sequence of the human TNF-R clone 1. Nucleotides are numbered from the beginning of the 5' untranslated region. Amino acids are numbered from the beginning of the signal peptide sequence. The putative signal peptide sequence is represented by the amino acids -22 to -1. The N-terminal leucine of the mature TNF-R protein is underlined at position 1. The predicted transmembrane region from amino acids 236 to 265 is also underlined. The C-termini of various soluble TNF-Rs are marked with an arrow (↑).

Figures 3A-3C depict the cDNA sequence and derived amino acid sequence of murine TNF-R clone 11. The putative signal peptide sequence is represented by amino acids -22 to -1. The N-terminal valine of the mature TNF-R protein is underlined at position 1. The predicted transmembrane region from amino acids 234 to 265 is also underlined.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein, the terms "TNF receptor" and "TNF-R" refer to proteins having amino acid sequences which are substantially similar to the native mammalian TNF receptor amino acid sequences, and which are biologically active, as defined below, in that they are capable of binding TNF molecules or transducing a biological signal initiated by a TNF molecule binding to a cell, or cross-reacting with anti-TNF-R antibodies raised against TNF-R from natural (i.e., nonrecombinant) sources. The mature full-length human TNF-R is a glycoprotein having a molecular weight of about 80 kilodaltons (kDa). As used throughout the specification, the term "mature" means a protein expressed in a form lacking a leader sequence as may be present in full-length transcripts of a native gene. Experiments using COS cells transfected with a cDNA encoding full-length human TNF-R showed that TNF-R bound ^{125}I-TNFα with an apparent K_a of about 5 x 10^9 M^{-1}, and that TNF-R bound ^{125}I-TNFβ with an apparent K_a of about 2 x 10^9 M^{-1}. The terms "TNF receptor" or "TNF-R" include, but are not limited to, analogs or subunits of native proteins having at least 20 amino acids and which exhibit at least some biological activity in common with TNF-R, for example, soluble TNF-R constructs which are devoid of a transmembrane region (and are secreted from the cell) but retain the ability to bind TNF. Various bioequivalent protein and amino acid analogs are described in detail below.

The nomenclature for TNF-R analogs as used herein follows the convention of naming the protein (e.g., TNF-R) preceded by either hu (for human) or mu (for murine) and followed by a Δ (to designate a deletion) and the number of the C-terminal amino acid. For example, huTNF-RΔ235 refers to human TNF-R having Asp^{235} as the C-terminal amino acid (i.e., a polypeptide having the sequence of amino acids 1-235 of ~~Figure 2A~~). In the absence of any human or murine species designation, TNF-R refers generically to mammalian TNF-R. Similarly, in the absence of any specific designation for deletion mutants, the term TNF-R means all forms of TNF-R, including mutants and analogs which possess TNF-R biological activity.

"Soluble TNF-R" or "sTNF-R" as used in the context of the present invention refer to proteins, or substantially equivalent analogs, having an amino acid sequence corresponding to all or part of the extracellular region of a native TNF-R, for example, huTNF-RΔ235, huTNF-RΔ185 and huTNF-RΔ163, or amino acid sequences substantially similar to the sequences of amino acids 1-163, amino acids 1-185, or amino acids 1-235 of ~~Figure 2A~~, and which are biologically active in that they bind to TNF ligand. Equivalent soluble TNF-Rs include polypeptides which vary from these sequences by one or more substitutions, deletions, or additions, and which retain the ability to bind TNF or inhibit TNF signal transduction activity via cell surface bound TNF receptor proteins, for example huTNF-RΔx, wherein x is selected from the group consisting of any one of amino acids 163-235 of ~~Figure 2A~~. Analogous deletions may be made to muTNF-R. Inhibition of TNF signal transduction activity can be determined by transfecting cells with recombinant TNF-R DNAs to obtain recombinant receptor expression. The cells are then contacted with TNF and the resulting metabolic effects examined. If an effect results which is attributable to the action of the ligand, then the recombinant receptor has signal transduction activity. Exemplary procedures for determining whether a polypeptide has signal transduction activity are disclosed by Idzerda et al., *J. Exp. Med. 171*:861 (1990); Curtis et al., *Proc. Natl. Acad. Sci. USA 86*:3045 (1989); Prywes et al., *EMBO J. 5*:2179 (1986) and Chou et al., *J. Biol. Chem. 262*:1842 (1987). Alternatively, primary cells or cell lines which express an endogenous TNF receptor and have a detectable biological response to TNF could also be utilized.

The term "isolated" or "purified", as used in the context of this specification to define the purity of TNF-R protein or protein compositions, means that the protein or protein composition is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes. Such compositions, however, can contain other proteins added as stabilizers, carriers, excipients or co-therapeutics. TNF-R is isolated if it is detectable as a single protein band in a polyacrylamide gel by silver staining.

The term "substantially similar," when used to define either amino acid or nucleic

acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity of the TNF-R protein as may be determined, for example, in one of the TNF-R binding assays set forth in Example 1 below. Alternatively, nucleic acid subunits and analogs are "substantially similar" to the specific DNA sequences disclosed herein if: (a) the DNA sequence is derived from the coding region of a native mammalian TNF-R gene; (b) the DNA sequence is capable of hybridization to DNA sequences of (a) under moderately stringent conditions (50°C, 2x SSC) and which encode biologically active TNF-R molecules; or DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b) and which encode biologically active TNF-R molecules.

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycan. Protein expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells.

"Biologically active," as used throughout the specification as a characteristic of TNF receptors, means that a particular molecule shares sufficient amino acid sequence similarity with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of TNF, transmitting a TNF stimulus to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti-TNF-R antibodies raised against TNF-R from natural (i.e., nonrecombinant) sources. Preferably, biologically active TNF receptors within the scope of the present invention are capable of binding greater than 0.1 nmoles TNF per nmole receptor, and most preferably, greater than 0.5 nmole TNF per nmole receptor in standard binding assays (see below).

"Isolated DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA

isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used as a source of coding sequences. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

"Nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. DNA sequences encoding the proteins provided by this invention can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.

Isolation of cDNAs Encoding TNF-R

The coding sequence of TNF-R is obtained by isolating a complementary DNA (cDNA) sequence encoding TNF-R from a recombinant cDNA or genomic DNA library. A cDNA library is preferably constructed by obtaining polyadenylated mRNA from a particular cell line which expresses a mammalian TNF-R, for example, the human fibroblast cell line WI-26 VA4 (ATCC CCL 95.1) and using the mRNA as a template for synthesizing double stranded cDNA. The double stranded cDNA is then packaged into a recombinant vector, which is introduced into an appropriate *E. coli* strain and propagated. Murine or other mammalian cell lines which express TNF-R may also be used. TNF-R sequences contained in the cDNA library can be readily identified by screening the library with an appropriate nucleic acid probe which is capable of hybridizing with TNF-R cDNA. Alternatively, DNAs encoding TNF-R proteins can be assembled by ligation of synthetic oligonucleotide subunits corresponding to all or part of the sequence of ~~Figures 2-3 or Figures 4-6~~ to provide a complete coding sequence.

The human TNF receptor cDNAs of the present invention were isolated by the

method of direct expression cloning. A cDNA library was constructed by first isolating cytoplasmic mRNA from the human fibroblast cell line WI-26 VA4. Polyadenylated RNA was isolated and used to prepare double-stranded cDNA. Purified cDNA fragments were then ligated into pCAV/NOT vector DNA which uses regulatory sequences derived from pDC201 (a derivative of pMLSV, previously described by Cosman et al., *Nature 312*:768, 1984), SV40 and cytomegalovirus DNA, described in detail below in Example 2. pCAV/NOT has been deposited with the American Type Culture Collection under accession No. ATCC 68014. The pCAV/NOT vectors containing the WI26-VA4 cDNA fragments were transformed into *E. coli* strain DH5a. Transformants were plated to provide approximately 800 colonies per plate. The resulting colonies were harvested and each pool used to prepare plasmid DNA for transfection into COS-7 cells essentially as described by Cosman et al. (*Nature 312*:768, 1984) and Luthman et al. (*Nucl. Acid Res. 11*:1295, 1983). Transformants expressing biologically active cell surface TNF receptors were identified by screening for their ability to bind ^{125}I-TNF. In this screening approach, transfected COS-7 cells were incubated with medium containing ^{125}I-TNF, the cells washed to remove unbound labeled TNF, and the cell monolayers contacted with X-ray film to detect concentrations of TNF binding, as disclosed by Sims et al, *Science 241:*585 (1988). Transfectants detected in this manner appear as dark foci against a relatively light background.

Using this approach, approximately 240,000 cDNAs were screened in pools of approximately 800 cDNAs until assay of one transfectant pool indicated positive foci for TNF binding. A frozen stock of bacteria from this positive pool was grown in culture and plated to provide individual colonies, which were screened until a single clone (clone 11) was identified which was capable of directing synthesis of a surface protein with detectable TNF binding activity. The sequence of cDNA clone 11 isolated by the above method is depicted in ~~Figures 4-6.~~

Additional cDNA clones can be isolated from cDNA libraries of other mammalian species by cross-species hybridization. For use in hybridization, DNA encoding TNF-R may be covalently labeled with a detectable substance such as a fluorescent group, a

radioactive atom or a chemiluminescent group by methods well known to those skilled in the art. Such probes could also be used for *in vitro* diagnosis of particular conditions.

Like most mammalian genes, mammalian TNF receptors are presumably encoded by multi-exon genes. Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein, are considered to be within the scope of the present invention.

Other mammalian TNF-R cDNAs are isolated by using an appropriate human TNF-R DNA sequence as a probe for screening a particular mammalian cDNA library by cross-species hybridization.

Proteins and Analogs

The present invention provides isolated recombinant mammalian TNF-R polypeptides. Isolated TNF-R polypeptides of this invention are substantially free of other contaminating materials of natural or endogenous origin and contain less than about 1% by mass of protein contaminants residual of production processes. The native human TNF-R molecules are recovered from cell lysates as glycoproteins having an apparent molecular weight by SDS-PAGE of about 80 kilodaltons (kDa). The TNF-R polypeptides of this invention are optionally without associated native-pattern glycosylation.

Mammalian TNF-R of the present invention includes, by way of example, primate, human, murine, canine, feline, bovine, ovine, equine and porcine TNF-R. Mammalian TNF-Rs can be obtained by cross species hybridization, using a single stranded cDNA derived from the human TNF-R DNA sequence as a hybridization probe to isolate TNF-R cDNAs from mammalian cDNA libraries.

Derivatives of TNF-R within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and carboxyl groups, for example, a TNF-R protein may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.

The primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to TNF-R amino acid side chains or at the N- or C-termini. Other derivatives of TNF-R within the scope of this invention include covalent or aggregative conjugates of TNF-R or its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated peptide may be a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co-translationally or post-translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the yeast α-factor leader). TNF-R protein fusions can comprise peptides added to facilitate purification or identification of TNF-R (e.g., poly-His). The amino acid sequence of TNF receptor can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (Hopp et al., *Bio/Technology* 6:1204, 1988.) The latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*.

TNF-R derivatives may also be used as immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures of TNF or other binding ligands. TNF-R derivatives may also be obtained by cross-linking agents, such as M-maleimidobenzoyl succinimide ester and N-hydroxysuccinimide, at cysteine and lysine residues. TNF-R proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromide-activated, bisoxirane-activated, carbonyldiimidazole-activated or tosyl-activated agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking). Once bound to a substrate, TNF-R may be used to selectively bind (for purposes of assay or

purification) anti-TNF-R antibodies or TNF.

The present invention also includes TNF-R with or without associated native-pattern glycosylation. TNF-R expressed in yeast or mammalian expression systems, e.g., COS-7 cells, may be similar or slightly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system. Expression of TNF-R DNAs in bacteria such as *E. coli* provides non-glycosylated molecules. Functional mutant analogs of mammalian TNF-R having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A_1-Z, where A_1 is any amino acid except Pro, and Z is Ser or Thr. In this sequence, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A_1 and Z, or an amino acid other than Asn between Asn and A_1.

TNF-R derivatives may also be obtained by mutations of TNF-R or its subunits. A TNF-R mutant, as referred to herein, is a polypeptide homologous to TNF-R but which has an amino acid sequence different from native TNF-R because of a deletion, insertion or substitution.

Bioequivalent analogs of TNF-R proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues can be deleted (e.g., Cys^{178}) or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. Generally, substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physiochemical characteristics resembling those of the residue to be replaced. Similarly, when a deletion or insertion strategy is adopted, the potential

effect of the deletion or insertion on biological activity should be considered. Substantially similar polypeptide sequences, as defined above, generally comprise a like number of amino acids sequences, although C-terminal truncations for the purpose of constructing soluble TNF-Rs will contain fewer amino acid sequences. In order to preserve the biological activity of TNF-Rs, deletions and substitutions will preferably result in homologous or conservatively substituted sequences, meaning that a given residue is replaced by a biologically similar residue. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known. Moreover, particular amino acid differences between human, murine and other mammalian TNF-Rs is suggestive of additional conservative substitutions that may be made without altering the essential biological characteristics of TNF-R.

Subunits of TNF-R may be constructed by deleting terminal or internal residues or sequences. Particularly preferred sequences include those in which the transmembrane region and intracellular domain of TNF-R are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium. The resulting protein is referred to as a soluble TNF-R molecule which retains its ability to bind TNF. A particularly preferred soluble TNF-R construct is TNF-RΔ235 (the sequence of amino acids 1-235 of Figure 2A), which comprises the entire extracellular region of TNF-R, terminating with Asp^{235} immediately adjacent the transmembrane region. Additional amino acids may be deleted from the transmembrane region while retaining TNF binding activity. For example, huTNF-RΔ183 which comprises the sequence of amino acids 1-183 of Figure 2A, and TNF-RΔ163 which comprises the sequence of amino acids 1-163 of Figure 2A, retain the ability to bind TNF ligand as determined using the binding assays described below in Example 1. TNF-RΔ142, however, does not retain the ability to bind TNF ligand. This suggests that one or both of Cys^{157} and Cys^{163} is required for formation of an intramolecular disulfide bridge for the proper folding of TNF-R. Cys^{178}, which was

deleted without any apparent adverse effect on the ability of the soluble TNF-R to bind TNF, does not appear to be essential for proper folding of TNF-R. Thus, any deletion C-terminal to Cys^{163} would be expected to result in a biologically active soluble TNF-R. The present invention contemplates such soluble TNF-R constructs corresponding to all or part of the extracellular region of TNF-R terminating with any amino acid after Cys^{163}. Other C-terminal deletions, such as TNF-FΔ157, may be made as a matter of convenience by cutting TNF-R cDNA with appropriate restriction enzymes and, if necessary, reconstructing specific sequences with synthetic oligonucleotide linkers. The resulting soluble TNF-R constructs are then inserted and expressed in appropriate expression vectors and assayed for the ability to bind TNF, as described in Example 1. Biologically active soluble TNF-Rs resulting from such constructions are also contemplated to be within the scope of the present invention.

Mutations in nucleotide sequences constructed for expression of analog TNF-R must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins which would adversely affect translation of the receptor mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed TNF-R mutants screened for the desired activity.

Not all mutations in the nucleotide sequence which encodes TNF-R will be expressed in the final product, for example, nucleotide substitutions may be made to enhance expression, primarily to avoid secondary structure loops in the transcribed mRNA (see EPA 75,444A, incorporated herein by reference), or to provide codons that are more readily translated by the selected host, e.g., the well-known *E. coli* preference codons for *E. coli* expression.

Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes

an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (*Gene 42*:133, 1986); Bauer et al. (*Gene 37*:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462 disclose suitable techniques, and are incorporated by reference herein.

Both monovalent forms and polyvalent forms of TNF-R are useful in the compositions and methods of this invention. Polyvalent forms possess multiple TNF-R binding sites for TNF ligand. For example, a bivalent soluble TNF-R may consist of two tandem repeats of amino acids 1-235 of ~~Figure 2A~~, separated by a linker region. Alternate polyvalent forms may also be constructed, for example, by chemically coupling TNF-R to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, polyethylene glycol or dextran using conventional coupling techniques. Alternatively, TNF-R may be chemically coupled to biotin, and the biotin-TNF-R conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/TNF-R molecules. TNF-R may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti-TNP-IgM, to form decameric conjugates with a valency of 10 for TNF-R binding sites.

A recombinant chimeric antibody molecule may also be produced having TNF-R sequences substituted for the variable domains of either or both of the [immunoglubulin] immunoglobulin molecule heavy and light chains and having unmodified constant region domains. For example, chimeric TNF-R/IgG_1 may be produced from two chimeric genes -- a TNF-R/human k light chain chimera (TNF-R/C_k) and a TNF-R/human γ_1 heavy chain chimera (TNF-R/$C_{\gamma 1}$). Following transcription and translation of the two chimeric genes, the gene products assemble into a single chimeric antibody molecule having TNF-R displayed bivalently. Such polyvalent forms of TNF-R may have enhanced binding affinity

for TNF ligand. Additional details relating to the construction of such chimeric antibody molecules are disclosed in WO 89/09622 and EP 315062.

Expression of Recombinant TNF-R

The present invention provides recombinant expression vectors to amplify or express DNA encoding TNF-R. Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding mammalian TNF-R or bioequivalent analogs operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below. Such regulatory elements may include an operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.

DNA sequences encoding mammalian TNF receptors which are to be expressed in a microorganism will preferably contain no introns that could prematurely terminate transcription of DNA into mRNA; however, premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C-terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Other embodiments include sequences capable of hybridizing to the sequences of the provided cDNA under moderately stringent conditions (50°C, 2x SSC) and other sequences hybridizing or degenerate to those which encode biologically active TNF receptor polypeptides.

Recombinant TNF-R DNA is expressed or amplified in a recombinant expression system comprising a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as *E. coli* or yeast such as *S. cerevisiae*, which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed.

Transformed host cells are cells which have been transformed or transfected with TNF-R vectors constructed using recombinant DNA techniques. Transformed host cells ordinarily express TNF-R, but host cells transformed for purposes of cloning or amplifying TNF-R DNA do not need to express TNF-R. Expressed TNF-R will be deposited in the cell membrane or secreted into the culture supernatant, depending on the TNF-R DNA selected. Suitable host cells for expression of mammalian TNF-R include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example *E. coli* or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below.

Cell-free translation systems could also be employed to produce mammalian TNF-R using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (*Cloning Vectors: A Laboratory Manual*, Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference.

Prokaryotic expression hosts may be used for expression of TNF-R that do not require extensive proteolytic and disulfide processing. Prokaryotic expression vectors generally comprise one or more phenotypic selectable markers, for example a gene encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli, Bacillus subtilis, Salmonella typhimurium*, and various species within the genera *Pseudomonas, Streptomyces*, and [*Staphyolococcus*] <u>*Staphylococcus*</u>, although others may also be employed as a matter of choice.

Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species (Bolivar et al., *Gene 2*:95, 1977). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.

Promoters commonly used in recombinant microbial expression vectors include the β-lactamase (penicillinase) and lactose promoter system (Chang et al., *Nature 275*:615, 1978; and Goeddel et al., *Nature 281*:544, 1979), the tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res. 8*:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory,

p. 412, 1982). A particularly useful bacterial expression system employs the phage λ P_L promoter and cI857ts thermolabile repressor. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2, resident in *E. coli* strain JMB9 (ATCC 37092) and pPLc28, resident in *E. coli* RR1 (ATCC 53082).

Recombinant TNF-R proteins may also be expressed in yeast hosts, preferably from the *Saccharomyces* species, such as *S. cerevisiae*. Yeast of other genera, such as *Pichia* or *Kluyveromyces* may also be employed. Yeast vectors will generally contain an origin of replication from the 2μ yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding TNF-R, sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and *E. coli*, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 or URA3 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the TRP1 or URA3 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan or uracil.

Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem. 255*:2073, 1980) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg. 7*:149, 1968; and Holland et al., *Biochem. 17*:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EPA 73,657.

Preferred yeast vectors can be assembled using DNA sequences from pUC18 for selection and replication in *E. coli* (Amp^r gene and origin of replication) and yeast DNA

sequences including a glucose-repressible ADH2 promoter and α-factor secretion leader. The ADH2 promoter has been described by Russell et al. (*J. Biol. Chem. 258*:2674, 1982) and Beier et al. (*Nature 300*:724, 1982). The yeast α-factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. *See, e.g.,* Kurjan et al., *Cell 30*:933, 1982; and Bitter et al., *Proc. Natl. Acad. Sci. USA 81*:5330, 1984. The leader sequence may be modified to contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.

Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA 75*:1929, 1978, selecting for Trp^+ transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 mg/ml adenine and 20 mg/ml uracil or URA+ tranformants in medium consisting of 0.67% YNB, with amino acids and bases as described by Sherman et al., *Laboratory Course Manual for Methods in Yeast Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986.

Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% or 4% glucose supplemented with 80 mg/ml adenine and 80 mg/ml uracil. Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4°C prior to further purification.

Various mammalian or insect cell culture systems are also advantageously employed to express recombinant protein. Expression of recombinant proteins in mammalian cells is particularly preferred because such proteins are generally correctly folded, appropriately modified and completely functional. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (*Cell 23*:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and

other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology 6*:47 (1988).

The transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources. For example, commonly used promoters and enhancers are derived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence. The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature 273*:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the *Hind* 3 site toward the *Bgl*1 site located in the viral origin of replication is included. Further, mammalian genomic TNF-R promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Additional details regarding the use of a mammalian high expression vector to produce a recombinant mammalian TNF receptor are provided in Examples 2 and 7 below. Exemplary vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol. 3*:280, 1983).

A useful system for stable high level expression of mammalian receptor cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (*Mol. Immunol. 23*:935, 1986).

In preferred aspects of the present invention, recombinant expression vectors comprising TNF-R cDNAs are stably integrated into a host cell's DNA. Elevated levels of expression product is achieved by selecting for cell lines having amplified numbers of vector DNA. Cell lines having amplified numbers of vector DNA are selected, for

example, by transforming a host cell with a vector comprising a DNA sequence which encodes an enzyme which is inhibited by a known drug. The vector may also comprise a DNA sequence which encodes a desired protein. Alternatively, the host cell may be co-transformed with a second vector which comprises the DNA sequence which encodes the desired protein. The transformed or co-transformed host cells are then cultured in increasing concentrations of the known drug, thereby selecting for drug-resistant cells. Such drug-resistant cells survive in increased concentrations of the toxic drug by over-production of the enzyme which is inhibited by the drug, frequently as a result of amplification of the gene encoding the enzyme. Where drug resistance is caused by an increase in the copy number of the vector DNA encoding the inhibitable enzyme, there is a concomitant co-amplification of the vector DNA encoding the desired protein (TNF-R) in the host cell's DNA.

A preferred system for such co-amplification uses the gene for dihydrofolate reductase (DHFR), which can be inhibited by the drug methotrexate (MTX). To achieve co-amplification, a host cell which lacks an active gene encoding DHFR is either transformed with a vector which comprises DNA sequence encoding DHFR and a desired protein, or is co-transformed with a vector comprising a DNA sequence encoding DHFR and a vector comprising a DNA sequence encoding the desired protein. The transformed or co-transformed host cells are cultured in media containing increasing levels of MTX, and those cells lines which survive are selected.

A particularly preferred co-amplification system uses the gene for glutamine synthetase (GS), which is responsible for the synthesis of glutamate and ammonia using the hydrolysis of ATP to ADP and phosphate to drive the reaction. GS is subject to inhibition by a variety of inhibitors, for example methionine sulphoximine (MSX). Thus, TNF-R can be expressed in high concentrations by co-amplifying cells transformed with a vector comprising the DNA sequence for GS and a desired protein, or co-transformed with a vector comprising a DNA sequence encoding GS and a vector comprising a DNA sequence encoding the desired protein, culturing the host cells in media containing increasing levels of MSX and selecting for surviving cells. The GS co-amplification

system, appropriate recombinant expression vectors and cells lines, are described in the following PCT applications: WO 87/04462, WO 89/01036, WO 89/10404 and WO 86/05807.

Recombinant proteins are preferably expressed by co-amplification of DHFR or GS in a mammalian host cell, such as Chinese Hamster Ovary (CHO) cells, or alternatively in a murine myeloma cell line, such as SP2/0-Ag14 or NS0 or a rat myeloma cell line, such as YB2/3.0-Ag20, disclosed in PCT applications WO/89/10404 and WO 86/05807.

A preferred eukaryotic vector for expression of TNF-R DNA is disclosed below in Example 2. This vector, referred to as pCAV/NOT, was derived from the mammalian high expression vector pDC201 and contains regulatory sequences from SV40, adenovirus-2, and human cytomegalovirus.

Purification of Recombinant TNF-R

Purified mammalian TNF receptors or analogs are prepared by culturing suitable host/vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts.

For example, supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. For example, a suitable affinity matrix can comprise a TNF or lectin or antibody molecule bound to a suitable support. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.

Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant

methyl or other aliphatic groups, can be employed to further purify a TNF-R composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant mammalian TNF-R can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Fermentation of yeast which express mammalian TNF-R as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large-scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (*J. Chromatog. 296*:171, 1984). This reference describes two sequential, reversed-phase HPLC steps for purification of recombinant human GM-CSF on a preparative HPLC column.

Human TNF-R synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which depend upon the purification steps taken to recover human TNF-R from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 1 percent by weight. Further, recombinant cell culture enables the production of TNF-R free of proteins which may be normally associated with TNF-R as it is found in nature in its species of origin, e.g. in cells, cell exudates or body fluids.

Therapeutic Administration of Recombinant Soluble TNF-R

The present invention provides methods of using therapeutic compositions comprising an effective amount of soluble TNF-R proteins and a suitable diluent and carrier, and methods for suppressing TNF-dependent inflammatory responses in humans

comprising administering an effective amount of soluble TNF-R protein.

For therapeutic use, purified soluble TNF-R protein is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, soluble TNF-R protein compositions can be administered by bolus injection, continuous infusion, sustained release from implants, or other suitable technique. Typically, a soluble TNF-R therapeutic agent will be administered in the form of a composition comprising purified protein in conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the TNF-R with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate diluents. Preferably, product is formulated as a lyophilizate using appropriate excipient solutions (e.g., sucrose) as diluents. Appropriate dosages can be determined in trials. The amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.

Soluble TNF-R proteins are administered for the purpose of inhibiting TNF-dependent responses. A variety of diseases or conditions are believed to be caused by TNF, such as cachexia and septic shock. In addition, other key cytokines (IL-1, IL-2 and other colony stimulating factors) can also induce significant host production of TNF. Soluble TNF-R compositions may therefore be used, for example, to treat cachexia or septic shock or to treat side effects associated with cytokine therapy. Because of the primary roles IL-1 and IL-2 play in the production of TNF, combination therapy using both IL-1 receptors or IL-2 receptors may be preferred in the treatment of TNF-associated clinical indications.

The following examples are offered by way of illustration, and not by way of

limitation.

EXAMPLES

Example 1

Binding Assays

A. *Radiolabeling of TNFα and TNFβ.* Recombinant human TNFα, in the form of a fusion protein containing a hydrophilic octapeptide at the N-terminus, was expressed in yeast as a secreted protein and purified by affinity chromatography (Hopp et al., *Bio/Technology 6*:1204, 1988). Purified recombinant human TNFβ was purchased from R&D Systems (Minneapolis, MN). Both proteins were radiolabeled using the commercially available solid phase agent, IODO-GEN (Pierce). In this procedure, 5 μg of IODO-GEN were plated at the bottom of a 10 x 75 mm glass tube and incubated for 20 minutes at 4°C with 75 μl of 0.1 M sodium phosphate, pH 7.4 and 20 μl (2 mCi) Na ^{125}I. This solution was then transferred to a second glass tube containing 5 μg TNFα (or TNFβ) in 45 μl PBS for 20 minutes at 4°C. The reaction mixture was fractionated by gel filtration on a 2 ml bed volume of Sephadex G-25 (Sigma) equilibrated in Roswell Park Memorial Institute (RPMI) 1640 medium containing 2.5% (w/v) bovine serum albumin (BSA), 0.2% (w/v) sodium azide and 20 mM Hepes pH 7.4 (binding medium). The final pool of ^{125}I-TNF was diluted to a working stock solution of 1 x 10^{-7} M in binding medium and stored for up to one month at 4°C without detectable loss of receptor binding activity. The specific activity is routinely 1 x 10^6 cpm/mmole TNF.

B. *Binding to Intact Cells.* Binding assays with intact cells were performed by two methods. In the first method, cells were first grown either in suspension (e.g., U 937) or by adherence on tissue culture plates (e.g., WI26-VA4, COS cells expressing the recombinant TNF receptor). Adherent cells were subsequently removed by treatment with 5mM EDTA treatment for ten minutes at 37 degrees centigrade. Binding assays were then performed by a [pthalate] phthalate oil separation method (Dower et al., *J. Immunol. 132*:751, 1984) essentially as described by Park et al. (*J. Biol. Chem. 261*:4177, 1986). Non-specific binding of ^{125}I-TNF was measured in the presence of a 200-fold or greater

molar excess of unlabeled TNF. Sodium azide (0.2%) was included in a binding assay to inhibit internalization of ^{125}I-TNF by cells. In the second method, COS cells transfected with the TNF-R-containing plasmid, and expressing TNF receptors on the surface, were tested for the ability to bind ^{125}I-TNF by the plate binding assay described by Sims et al. (*Science 241*:585, 1988).

C. *Solid Phase Binding Assays*. The ability of TNF-R to be stably adsorbed to nitrocellulose from detergent extracts of human cells yet retain TNF-binding activity provided a means of detecting TNF-R. Cell extracts were prepared by mixing a cell pellet with a 2 x volume of PBS containing 1% Triton X-100 and a cocktail of protease inhibitors (2 mM phenylmethyl sulfonyl fluoride, 10 μM pepstatin, 10 μM leupeptin, 2 mM o-phenanthroline and 2 mM EGTA) by vigorous vortexing. The mixture was incubated on ice for 30 minutes after which it was centrifuged at 12,000x g for 15 minutes at 8°C to remove nuclei and other debris. Two microliter aliquots of cell extracts were placed on dry BA85/21 nitrocellulose membranes (Schleicher and Schuell, Keene, NH) and allowed to dry. The membranes were incubated in tissue culture dishes for 30 minutes in Tris (0.05 M) buffered saline (0.15 M) pH 7.5 containing 3% w/v BSA to block nonspecific binding sites. The membrane was then covered with 5 x 10^{-11} M ^{125}I-TNF in PBS + 3% BSA and incubated for 2 hr at 4°C with shaking. At the end of this time, the membranes were washed 3 times in PBS, dried and placed on Kodak X-Omat AR film for 18 hr at -70°C.

Example 2

Isolation of Human TNF-R cDNA by Direct Expression of Active Protein in COS-7 Cells

Various human cell lines were screened for expression of TNF-R based on their ability to bind ^{125}I-labeled TNF. The human fibroblast cell line WI-26 VA4 was found to express a reasonable number of receptors per cell. Equilibrium binding studies showed that the cell line exhibited biphasic binding of ^{125}I-TNF with approximately 4,000 high affinity

sites (K_a = 1 x 10^{10} M^{-1}) and 15,00 low affinity sites (K_a = 1 x 10^8 M^{-1}) per cell.

An unsized cDNA library was constructed by reverse transcription of polyadenylated mRNA isolated from total RNA extracted from human fibroblast WI-26 VA4 cells grown in the presence of pokeweed mitogen using standard techniques (Gubler, et al., *Gene 25*:263, 1983; Ausubel et al., eds., *Current Protocols in Molecular Biology*, Vol. 1, 1987). The cells were harvested by lysing the cells in a guanidine hydrochloride solution and total RNA isolated as previously described (March et al., *Nature 315*:641, 1985).

Poly A^+ RNA was isolated by oligo dT cellulose chromatography and double-stranded cDNA was prepared by a method similar to that of Gubler and Hoffman (*Gene 25*:263, 1983). Briefly, the poly A^+ RNA was converted to an RNA-cDNA hybrid by reverse transcriptase using oligo dT as a primer. The RNA-cDNA hybrid was then converted into double-stranded cDNA using RNAase H in combination with DNA polymerase I. The resulting double stranded cDNA was blunt-ended with T4 DNA polymerase. To the blunt-ended cDNA is added *EcoR*I linker-adapters (having internal *Not*1 sites) which were phosphorylated on only one end (Invitrogen). The linker-adaptered cDNA was treated with T4 polynucleotide kinase to phosphorylate the 5' overhanging region of the linker-adapter and unligated linkers were removed by running the cDNA over a Sepharose CL4B column. The linker-adaptered cDNA was ligated to an equimolar concentration of *EcoR*1 cut and dephosphorylated arms of bacteriophage λgt10 (Huynh et al, *DNA Cloning: A Practical Approach*, Glover, ed., IRL Press, pp. 49-78). The ligated DNA was packaged into phage particles using a commercially available kit to generate a library of recombinants (Stratagene Cloning Systems, San Diego, CA, USA). Recombinants were further amplified by plating phage on a bacterial lawn of *E. coli* strain c600(hfl$^-$).

Phage DNA was purified from the resulting λgt10 cDNA library and the cDNA inserts excised by digestion with the restriction enzyme *Not*1. Following electrophoresis of the digest through an agarose gel, cDNAs greater than 2,000 bp were isolated.

The resulting cDNAs were ligated into the eukaryotic expression vector

pCAV/NOT, which was designed to express cDNA sequences inserted at its multiple cloning site when transfected into mammalian cells. pCAV/NOT was assembled from pDC201 (a derivative of pMLSV, previously described by Cosman et al., *Nature 312*: 768, 1984), SV40 and cytomegalovirus DNA and comprises, in sequence with the direction of transcription from the origin of replication: (1) SV40 sequences from coordinates 5171-270 including the origin of replication, enhancer sequences and early and late promoters; (2) cytomegalovirus sequences including the promoter and enhancer regions (nucleotides 671 to +63 from the sequence published by Boechart et al. (*Cell 41*:521, 1985); (3) adenovirus-2 sequences containing the first exon and part of the intron between the first and second exons of the tripartite leader, the second exon and part of the third exon of the tripartite leader and a multiple cloning site (MCS) containing sites for Xho1, Kpn1, Sma1, Not1 and *Bgl*1; (4) SV40 sequences from coordinates 4127-4100 and 2770-2533 that include the polyadenylation and termination signals for early transcription; (5) sequences derived from pBR322 and virus-associated sequences VAI and VAII of pDC201, with adenovirus sequences 10532-11156 containing the VAI and VAII genes, followed by pBR322 sequences from 4363-2486 and 1094-375 containing the ampicillin resistance gene and origin of replication.

The resulting WI-26 VA4 cDNA library in pCAV/NOT was used to transform *E. coli* strain DH5α, and recombinants were plated to provide approximately 800 colonies per plate and sufficient plates to provide approximately 50,000 total colonies per screen. Colonies were scraped from each plate, pooled, and plasmid DNA prepared from each pool. The pooled DNA was then used to transfect a sub-confluent layer of monkey COS-7 cells using DEAE-dextran followed by chloroquine treatment, as described by Luthman et al. (*Nucl. Acids Res. 11*:1295, 1983) and McCutchan et al. (*J. Natl. Cancer Inst. 41*:351, 1986). The cells were then grown in culture for three days to permit transient expression of the inserted sequences. After three days, cell culture supernatants were discarded and the cell monolayers in each plate assayed for TNF binding as follows. Three ml of binding medium containing 1.2×10^{-11} M ^{125}I-labeled FLAG®-TNF was added to each plate and the plates incubated at 4°C for 120 minutes. This medium was then discarded, and each plate

was washed once with cold binding medium (containing no labeled TNF) and twice with cold PBS. The edges of each plate were then broken off, leaving a flat disk which was contacted with X-ray film for 72 hours at -70°C using an intensifying screen. TNF binding activity was visualized on the exposed films as a dark focus against a relatively uniform background.

After approximately 240,000 recombinants from the library had been screened in this manner, one transfectant pool was observed to provide TNF binding foci which were clearly apparent against the background exposure.

A frozen stock of bacteria from the positive pool was then used to obtain plates of approximately 150 colonies. Replicas of these plates were made on nitrocellulose filters, and the plates were then scraped and plasmid DNA prepared and transfected as described above to identify a positive plate. Bacteria from individual colonies from the nitrocellulose replica of this plate were grown in 0.2 ml cultures, which were used to obtain plasmid DNA, which was transfected into COS-7 cells as described above. In this manner, a single clone, clone 1, was isolated which was capable of inducing expression of human TNF-R in COS cells. The expression vector pCAV/NOT containing the TNF-R cDNA clone 1 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA (Accession No. 68088) under the name pCAV/NOT-TNF-R.

Example 3

Construction of cDNAs Encoding Soluble huTNF-RΔ235

A cDNA encoding a soluble huTNF-RΔ235 (having the sequence of amino acids 1-235 of ~~Figure 2A~~) was constructed by excising an 840 bp fragment from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Pvu2. Not1 cuts at the multiple cloning site of pCAV/NOT-TNF-R and Pvu2 cuts within the TNF-R coding region 20 nucleotides 5' of the transmembrane region. In order to reconstruct the 3' end of the TNF-R sequences, two oligonucleotides were synthesized and annealed to create the following oligonucleotide linker:

```
                    Pvu2                        BamH1 Bgl2
                    CTGAAGGGAGCACTGGCGACTAAGGATCCA
                    GACTTCCCTCGTGACCGCTGATTCCTAGGTCTAG
                  AlaGluGlySerThrGlyAspEnd
```

This oligonucleotide linker has terminal Pvu2 and Bgl2 restriction sites, regenerates 20 nucleotides of the TNF-R, followed by a termination codon (underlined) and a BamH1 restriction site (for convenience in isolating the entire soluble TNF-R by Not1/BamH1 digestion). This oligonucleotide was then ligated with the 840 bp Not1/Pvu2 TNF-R insert into Bgl2/Not1 cut pCAV/NOT to yield psolhuTNF-RΔ235/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF.

Example 4

Construction of cDNAs Encoding Soluble huTNF-RΔ185

A cDNA encoding a soluble huTNF-RΔ185 (having the sequence of amino acids 1-185 of ~~Figure 2A~~) was constructed by excising a 640 bp fragment from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Bgl2. Not1 cuts at the multiple cloning site of pCAV/NO-TNF-R and Bgl2 cuts within the TNF-R coding region at nucleotide 637, which is 237 nucleotides 5' of the transmembrane region. The following oligonucleotide linkers were synthesized:

```
      Bgl2
5'-GATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGC-3'
       ACATTGCACCACCGGTAGGGACCCTTACGTTCG
    IleCysAsnValValAlaIleProGlyAsnAlaSerMetAspAla


                                                Not1
5'-        AGTCTGCACGTCCACGTCCCCCACCCGGTGAGC     -3'
   TACCTACGTCAGACGTGCAGGTGCAGGGGGTGGGCCACTCGCCGG
            ValCysThrSerThrSerProThrArgEnd
```

The above oligonucleotide linkers reconstruct the 3' end of the receptor molecule up to nucleotide 708, followed by a termination codon (underlined). These oligonucleotides were

then ligated with the 640 bp Not1 TNF-R insert into Not1 cut pCAV/NOT to yield the expression vector psolTNFRΔ185/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF.

Example 5

Construction of cDNAs Encoding Soluble huTNF-RΔ163

A cDNA encoding a soluble huTNF-RΔ163 (having the sequence of amino acids 1-163 of ~~Figure 2A)~~ was constructed by excising a 640 bp fragment from pCAV/NOT-TNF-R with the restriction enzymes Not1 and Bgl2 as described in Example 4. The following oligonucleotide linkers were synthesized:

```
   Bgl2          Not1
5'-GATCTGTTGAGC      -3'
       ACAACTCGCCGG
    IleCysEnd
```

This above oligonucleotide linker reconstructs the 3' end of the receptor molecule up to nucleotide 642 (amino acid 163), followed by a termination codon (underlined). This oligonucleotide was then ligated with the 640 bp Not1 TNF-R insert into Not1 cut pCAV/NOT to yield the expression vector psolTNFRΔ163/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector induced expression of soluble human TNF-R which was capable of binding TNF in the binding assay described in Example 1.

Example 6

Construction of cDNAs Encoding Soluble huTNF-RΔ142

A cDNA encoding a soluble huTNF-RΔ142 (having the sequence of amino acids 1-142 of ~~Figure 2A)~~ was constructed by excising a 550 bp fragment from

pCAV/NOT-TNF-R with the restriction enzymes Not1 and AlwN1. AlwN1 cuts within the TNF-R coding region at nucleotide 549. The following oligonucleotide linker was synthesized:

```
   Bgl2          Not1
5'-CTGAAACATCAGACGTGGTGTGCAAGCCCTGTTAAA-3'
CTTGACTTTGTAGTCTGCACCACACGTTCGGGACAATTTCTAGA
                                      End
```

This above oligonucleotide linker reconstructs the 3' end of the receptor molecule up to nucleotide 579 (amino acid 142), followed by a termination codon (underlined). This oligonucleotide was then ligated with the 550 bp Not1/AlwN1 TNF-R insert into Not1/Bgl2 cut pCAV/NOT to yield the expression vector psolTNFRΔ142/CAVNOT, which was transfected into COS-7 cells as described above. This expression vector did not induced expression of soluble human TNF-R which was capable of binding TNF. It is believed that this particular construct failed to express biologically active TNF-R because one or more essential cysteine residue (e.g., Cys^{157} or Cys^{163}) required for intramolecular bonding (for formation of the proper tertiary structure of the TNF-R molecule) was eliminated.

Example 7

Expression of Soluble TNF Receptors in CHO Cells

Soluble TNF receptor was expressed in Chinese Hamster Ovary (CHO) cells using the glutamine-synthetase (GS) gene amplification system, substantially as described in PCT patent application Nos. WO87/04462 and WO89/01036. Briefly, CHO cells are transfected with an expression vector containing genes for both TNF-R and GS. CHO cells are selected for GS gene expression based on the ability of the transfected DNA to confer resistance to low levels of methionine sulphoximine (MSX). GS sequence amplification events in such cells are selected using elevated MSX concentrations. In this way, contiguous TNF-R sequences are also amplified and enhanced TNF-R expression is achieved.

The vector used in the GS expression system was psolTNFR/P6/PSVLGS, which

was constructed as follows. First, the vector pSVLGS.1 (described in PCT Application Nos. WO87/04462 and WO89/01036, and available from Celltech, Ltd., Berkshire, UK) was cut with the BamH1 restriction enzyme and dephosphorylated with calf intestinal alkaline phosphatase (CIAP) to prevent the vector from religating to itself. The BamH1 cut pSVLGS.1 fragment was then ligated to a 2.4 kb BamH1 to Bgl2 fragment of pEE6hCMV (described in PCT Application No. WO89/01036, also available from Celltech) which was cut with Bgl2, BamH1 and Fsp1 to avoid two fragments of similar size, to yield an 11.2 kb vector designated p6/PSVLGS.1. pSVLGS.1 contains the glutamine synthetase selectable marker gene under control of the SV40 later promoter. The BamH1 to Bgl2 fragment of pEE6hCMV contains the human cytomegalovirus major immediate early promoter (hCMV), a polylinker, and the SV40 early polyadenylation signal. The coding sequences for soluble TNF-R were added to p6/PSVLGS.1 by excising a Not1 to BamH1 fragment from the expression vector psolTNFR/CAVNOT (made according to Example 3 above), blunt ending with Klenow and ligating with SmaI cut dephosphorylated p6/PSVLGS.1, thereby placing the solTNF-R coding sequences under the control of the hCMV promoter. This resulted in a single plasmid vector in which the SV40/GS and hCMB/solTNF-R transcription units are transcribed in opposite directions. This vector was designated psolTNFR/P6/PSVLGS.

psolTNFR/P6/PSVLGS was used to transfect CHO-K1 cells (available from ATCC, Rochville, MD, under accession number CCL 61) as follows. A monolayer of CHO-K1 cells were grown to subconfluency in Minimum Essential Medium (MEM) 10X (Gibco: 330-1581AJ) without glutamine and supplemented with 10% dialysed fetal bovine serum (Gibco: 220-6300AJ), 1 mM sodium pyruvate (Sigma), MEM non-essential amino acids (Gibco: 320-1140AG), 500 μM asparagine and glutamate (Sigma) and nucleosides (30 μM adenosine, guanosine, cytidine and uridine and 10 μM thymidine)(Sigma).

Approximately 1 x 10^6 cells per 10 cm petri dish were transfected with 10 μg of psolTNFR/P6/PSVLGS by standard calcium phosphate precipitation, substantially as described by Graham & van der Eb, *Virology 52*:456 (1983). Cells were subjected to glycerol shock (15% glycerol in serum-free culture medium for approximately 1.5 minutes)

approximately 4 hours after transfection, substantially as described by Frost & Williams, *Virology 91*:39 (1978), and then washed with serum-free medium. One day later, transfected cells were fed with fresh selective medium containing MSX at a final concentration of 25 [uM] μM. Colonies of MSX-resistant surviving cells were visible within 3-4 weeks. Surviving colonies were transferred to 24-well plates and allowed to grow to confluency in selective medium. Conditioned medium from confluent wells were then assayed for soluble TNF-R activity using the binding assay described in Example 1 above. These assays indicated that the colonies expressed biologically active soluble TNF-R.

In order to select for GS gene amplification, several MSX-resistant cell lines are transfected with psolTNFR/P6/PSVLGS and grown in various concentrations of MSX. For each cell line, approximately $1x10^6$ cells are plated in gradually increasing concentrations of 100 [uM] μM, 250 [uM] μM, 500 [uM] μM and 1 mM MSX and incubated for 10-14 days. After 12 days, colonies resistant to the higher levels of MSX appear. The surviving colonies are assayed for TNF-R activity using the binding assay described above in Example 1. Each of these highly resistant cell lines contains cells which arise from multiple independent amplification events. From these cells lines, one or more of the most highly resistant cells lines are isolated. The amplified cells with high production rates are then cloned by limiting dilution cloning. Mass cell cultures of the transfectants secrete active soluble TNF-R.

Example 8

Expression of Soluble Human TNF-R in Yeast

Soluble human TNF-R was expressed in yeast with the expression vector pIXY432, which was derived from the yeast expression vector pIXY120 and plasmid pYEP352. pIXY120 is identical to pYαHuGM (ATCC 53157), except that it contains no cDNA insert and includes a polylinker/multiple cloning site with a Nco1 restriction site.

A DNA fragment encoding TNF receptor and suitable for cloning into the yeast expression vector pIXY120 was first generated by polymerase chain reaction (PCR)

amplification of the extracellular portion of the full length receptor from pCAV/NOT-TNF-R (ATCC 68088). The following primers were used in this PCR amplification:

5' End Primer

```
5'-TTCCGGTACCTTTGGATAAAAGAGACTACAAGGAC
   Asp718->ProLeuAspLysArgAspTyrLysAsp
      GACGATGACAAGTTGCCCGCCCAGGTGGCATTTACA-3'
         AspAspAspLys<---------- TNF-R ---------->
```

3' End Primer (antisense)

```
5'-CCCGGGATCCTTAGTCGCCAGTGCTCCCTTCAGCTGGG-3'
       BamH1>End<----------TNF-R---------->
```

The 5' end oligonucleotide primer used in the amplification included an Asp718 restriction site at its 5' end, followed by nucleotides encoding the 3' end of the yeast a-factor leader sequence (Pro-Leu-Asp-Lys-Arg) and those encoding the 8 amino acids of the FLAG® peptide (AspTyrLysAspAspAspAspLys) fused to sequence encoding the 5' end of the mature receptor. The FLAG® peptide (Hopp et al., *Bio/Technology* 6:1204, 1988) is a highly antigenic sequence which reversibly binds the monoclonal antibody M1 (ATCC HB 9259). The oligonucleotide used to generate the 3' end of the PCR-derived fragment is the *antisense* strand of DNA encoding sequences which terminate the open reading frame of the receptor after nucleotide 704 of the mature coding region (following the Asp residue preceding the transmembrane domain) by introducing a TAA stop codon (underlined). The stop codon is then followed by a BamH1 restriction site. The DNA sequences encoding TNF-R are then amplified by PCR, substantially as described by Innis et al., eds., *PCR Protocols: A Guide to Methods and Applications* (Academic Press, 1990).

The PCR-derived DNA fragment encoding soluble human TNF-R was subcloned into the yeast expression vector pIXY120 by digesting the PCR-derived DNA fragment with BamH1 and Asp718 restriction enzymes, digesting pIXY120 with BamH1 and Asp718, and ligating the PCR fragment into the cut vector *in vitro* with T4 DNA ligase. The resulting construction (pIXY424) fused the open reading frame of the FLAG®-soluble

TNF receptor in-frame to the complete a-factor leader sequence and placed expression in yeast under the aegis of the regulated yeast alcohol dehydrogenase (ADH2) promoter. Identity of the nucleotide sequence of the soluble TNF receptor carried in pIXY424 with those in cDNA clone 1 were verified by DNA sequencing using the dideoxynucleotide chain termination method. pIXY424 was then transformed into *E. coli* strain RR1.

Soluble human TNF receptor was also expressed and secreted in yeast in a second vector. This second vector was generated by recovering the pIXY424 plasmid from *E. coli* and digesting with EcoR1 and BamH1 restriction enzymes to isolate the fragment spanning the region encoding the ADH2 promoter, the α-factor leader, the FLAG®-soluble TNF receptor and the stop codon. This fragment was ligated *in vitro* into EcoR1 and BamH1 cut plasmid pYEP352 (Hill et al., *Yeast 2*:163 (1986)), to yield the expression plasmid pIXY432, which was transformed into *E.coli* strain RR1.

To assess secretion of the soluble human TNF receptor from yeast, pIXY424 was purified and introduced into a diploid yeast strain of *S. cerevisiae* (XV2181) by electroporation and selection for acquisition of the plasmid-borne yeast $TRP1^+$ gene on media lacking tryptophan. To assess secretion of the receptor directed by pIXY432, the plasmid was introduced into the yeast strain PB149-6b by electroporation followed by selection for the plasmid-borne $URA3^+$ gene with growth on media lacking uracil. Overnight cultures were grown at 30°C in the appropriate selective media. The PB149-6b/pIXY434 transformants were diluted into YEP-1% glucose media and grown at 30°C for 38-40 hours. Supernatants were prepared by removal of cells by centrifugation, and filtration of supernatants through 0.45μ filters.

The level of secreted receptor in the supernatants was determined by immuno-dotblot. Briefly, 1 ul of supernatants, and dilutions of the supernatants, were spotted onto nitrocellulose filters and allowed to dry. After blocking non-specific protein binding with a 3% BSA solution, the filters were incubated with diluted M1 anti-FLAG® antibody, excess antibody was removed by washing and then dilutions of horseradish peroxidase conjugated anti-mouse IgG antibodies were incubated with the filters. After removal of excess secondary antibodies, peroxidase substrates were added and color

development was allowed to proceed for approximately 10 minutes prior to removal of the substrate solution.

The anti-FLAG® reactive material found in the supernatants demonstrated that significant levels of receptor were secreted by both expression systems. Comparisons demonstrated that the pIXY432 system secreted approximately 8-16 times more soluble human TNF receptor than the pIXY424 system. The supernatants were assayed for soluble TNF-R activity, as described in Example 1, by their ability to bind ^{125}I-TNFα and block TNFα binding. The pIXY432 supernatants were found to contain significant levels of active soluble TNF-R.

Example 9

Isolation of Murine TNF-R cDNAs

Murine TNF-R cDNAs were isolated from a cDNA library made from murine 7B9 cells, an antigen-dependent helper T cell line derived from C57BL/6 mice, by cross-species hybridization with a human TNF-R probe. The cDNA library was constructed in λZAP (Stratagene, San Diego), substantially as described above in Example 2, by isolating polyadenylated RNA from the 7B9 cells.

A double-stranded human TNF-R cDNA probe was produced by excising an approximately 3.5 kb NotI fragment of the human TNF-R clone 1 and ^{32}P-labeling the cDNA using random primers (Boehringer-Mannheim).

The murine cDNA library was amplified once and a total of 900,000 plaques were screened, substantially as described in Example 2, with the human TNF-R cDNA probe. Approximately 21 positive plaques were purified, and the Bluescript plasmids containing EcoR1-linkered inserts were excised (Stratagene, San Diego). Nucleic acid sequencing of a portion of murine TNF-R clone 11 indicated that the coding sequence of the murine TNF-R was approximately 88% homologous to the corresponding nucleotide sequence of human TNF-R. A partial nucleotide sequence of murine TNF-R cDNA clone 11 is set forth in ~~Figures 3A-3B.~~

Example 10

Preparation of Monoclonal Antibodies to TNF-R

Preparations of purified recombinant TNF-R, for example, human TNF-R, or transfected COS cells expressing high levels of TNF-R are employed to generate monoclonal antibodies against TNF-R using conventional techniques, for example, those disclosed in U.S. Patent 4,411,993. Such antibodies are likely to be useful in interfering with TNF binding to TNF receptors, for example, in ameliorating toxic or other undesired effects of TNF, or as components of diagnostic or research assays for TNF or soluble TNF receptor.

To immunize mice, TNF-R immunogen is emulsified in complete Freund's adjuvant and injected in amounts ranging from 10-100 μg subcutaneously into Balb/c mice. Ten to twelve days later, the immunized animals are boosted with additional immunogen emulsified in incomplete Freund's adjuvant and periodically boosted thereafter on a weekly to biweekly immunization schedule. Serum samples are periodically taken by retro-orbital bleeding or tail-tip excision for testing by dot-blot assay (antibody sandwich) or ELISA (enzyme-linked immunosorbent assay). Other assay procedures are also suitable. Following detection of an appropriate antibody titer, positive animals are given an intravenous injection of antigen in saline. Three to four days later, the animals are sacrificed, splenocytes harvested, and fused to the murine myeloma cell line NS1. Hybridoma cell lines generated by this procedure are plated in multiple microtiter plates in a HAT selective medium (hypoxanthine, aminopterin, and thymidine) to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

Hybridoma clones thus generated can be screened by ELISA for reactivity with TNF-R, for example, by adaptations of the techniques disclosed by Engvall et al., *Immunochem. 8*:871 (1971) and in U.S. Patent 4,703,004. Positive clones are then injected into the peritoneal cavities of syngeneic Balb/c mice to produce ascites containing high concentrations (>1 mg/ml) of anti-TNF-R monoclonal antibody. The resulting monoclonal antibody can be purified by ammonium sulfate precipitation followed by gel exclusion

chromatography, and/or affinity chromatography based on binding of antibody to Protein A of *Staphylococcus aureus*.

What is claimed is:

Claim 1. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence capable of hybridization to the complement of the DNA sequence of (a) under moderately stringent conditions (50°C., 2x SSC) and which encodes a polypeptide that is capable of binding to TNF and which is at least 88% identical to a polypeptide encoded by the DNA of (a).

Claim 2. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence capable of hybridization to the complement of the DNA sequence of (a) under moderately stringent conditions (50°C., 2x SSC) and which encodes TNF-R protein that is capable of binding greater than 0.1 moles TNF per nmole TNF-R and which is at least 88% identical to a polypeptide encoded by the DNA of (a).

Claim 3. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence capable of hybridization to the complement of the DNA sequence of (a) under moderately stringent conditions (50°C., 2x SSC) and which encodes TNF-R protein that is capable of binding greater than 0.5 nmoles TNF per nmole TNF-R and which is at least 88% identical to a polypeptide encoded by the DNA of (a).

Claim 4. A recombinant expression vector comprising the DNA sequence according to claim 1.

Claim 5. A recombinant expression vector comprising the DNA sequence according to claim 2.

Claim 6. A recombinant expression vector comprising the DNA sequence according to claim 3.

Claim 7. A host cell transformed or transfected with the vector according to claim 4.

Claim 8. A host cell transformed or transfected with the vector according to claim 5.

Claim 9. A host cell transformed or transfected with the vector according to claim 6.

Claim 10. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence that encodes a polypeptide identical to the polypeptide encoded by the DNA of (a) except for modification(s) to the amino acid sequence selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; (iii) conservative amino acid substitutions; (iv) substitution or deletion of cysteine residues; and

(v) combinations of modifications (i)-(iv); which such polypeptide is capable of binding TNF.

Claim 11. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence that encodes a polypeptide identical to the polypeptide encoded by the DNA of (a) except for modification(s) to the amino acid sequence selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; (iii) conservative amino acid substitutions; (iv) substitution or deletion of cysteine residues; and (v) combinations of modifications (i)-(iv); which encoded polypeptide is capable of binding greater than 0.1 moles TNF per nmole of such polypeptide.

Claim 12. An isolated DNA sequence selected from the group consisting of:

(a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233 of FIG. 3A, wherein X is an amino acid from 163 to 235; and

(b) a DNA sequence that encodes a polypeptide identical to the polypeptide encoded by the DNA of (a) except for modification(s) to the amino acid sequence selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; (iii) conservative amino acid substitutions; (iv) substitution or deletion of cysteine residues; and (v) combinations of modifications (i)-(iv); which encoded

polypeptide is capable of binding greater than 0.5 moles TNF per nmole of such polypeptide.

Claim 13. A recombinant expression vector comprising the DNA according to any one of claims 10, 11 or 12.

Claim 14. A host cell transformed or transfected with the vector according to claim 13.

Claim 15. A DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of (a) amino acids 1-235 of FIG. 2A; and (b) a DNA sequence capable of hybridization to the DNA sequence of (a) under moderately stringent conditions (50°C., 2x SSC) and which encodes a polypeptide that is capable of binding to TNF and which is at least 88% identical to a polypeptide encoded by the DNA of (a).

Claim 16. A recombinant expression vector comprising the DNA sequence according to claim 15.

Claim 17. A host cell transformed or transfected with the vector according to claim 16.

Claim 18. An isolated DNA molecule encoding a protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of FIG. 2A and amino acids 1-233 of FIG. 3A, wherein said protein is capable of binding TNF.

Claim 19. The isolated DNA molecule according to Claim 18, wherein said protein comprises amino acids 1-163 of FIG. 2A.

Claim 20. The isolated DNA molecule according to Claim 18, wherein said protein comprises amino acids 1-185 of FIG. 2A.

Claim 21. The isolated DNA molecule according to Claim 18, wherein said protein comprises amino acids 1-235 of FIG. 2A.

Claim 22. An isolated DNA molecule encoding a protein selected from the group consisting of:

(a) a polypeptide having a sequence of amino acids comprising amino acids 1-163 of FIG. 2A;

(b) a polypeptide having a sequence of amino acids comprising amino acids 1-233 of FIG. 3A; and

(c) a polypeptide identical to the polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues,

wherein said protein is capable of binding TNF.

Claim 23. A recombinant expression vector comprising the DNA molecule according to Claim 18, 19, 20, 21 or 22.

Claim 24. A host cell transformed or transfected with the recombinant expression vector according to Claim 23.

Claim 25. The host cell of Claim 24, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 26. The host cell of Claim 25, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 27. The host cell of Claim 26, wherein said mammalian cell is CHO cells.

Claim 28. A process for producing a protein capable of binding TNF, said process comprising culturing a host cell of Claim 24 under conditions suitable to effect expression of said protein.

Claim 29. The process of Claim 28, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 30. The process of Claim 29, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 31. The process of Claim 30, wherein said mammalian cell is CHO cells.

Claim 32. An isolated DNA molecule encoding a soluble TNF receptor protein comprising a sequence of amino acids selected from the group consisting of from about amino acid 1 to about amino acid 163 of FIG. 2A and from about amino acid 1 to about amino acid 233 of FIG. 3A, wherein said soluble TNF receptor protein is capable of binding TNF protein.

Claim 33. The isolated DNA molecule according to Claim 32, wherein said soluble TNF receptor protein comprises from about amino acid 1 to about amino acid 163 of FIG. 2A.

Claim 34. The isolated DNA molecule according to Claim 32, wherein said soluble TNF receptor protein comprises from about amino acid 1 to about amino acid 185 of FIG. 2A.

Claim 35. The isolated DNA molecule according to Claim 32, wherein said TNF soluble receptor protein comprises from about amino acid 1 to about amino acid 235 of FIG. 2A.

Claim 36. An isolated DNA molecule encoding a soluble TNF receptor protein selected from the group consisting of:

(a) a TNF receptor polypeptide having a sequence of amino acids comprising from about amino acid 1 to about amino acid 163 of FIG. 2A;

(b) a TNF receptor polypeptide having a sequence of amino acids comprising from about amino acid 1 to about amino acid 233 of FIG. 3A; and

(c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues,

wherein said soluble TNF receptor protein is capable of binding TNF.

Claim 37. A recombinant expression vector comprising the DNA molecule according to Claim 32, 33, 34, 35 or 36.

Claim 38. A host cell transformed or transfected with the recombinant expression vector according to Claim 37.

Claim 39. The host cell of Claim 38, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 40. The host cell of Claim 39, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 41. The host cell of Claim 40, wherein said mammalian cell is CHO cells.

Claim 42. A process for producing a protein capable of binding TNF, said process comprising culturing a host cell of Claim 38 under conditions suitable to effect expression of said protein.

Claim 43. The process of Claim 42, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 44. The process of Claim 43, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 45. The process of Claim 44, wherein said mammalian cell is CHO cells.

Claim 46. An isolated DNA molecule encoding a soluble TNF receptor protein comprising a sequence of amino acids selected from the group consisting of from amino acid 1 to amino acid 163 of FIG. 2A and from amino acid 1 to amino acid 233 of FIG. 3A, wherein said soluble TNF receptor protein is capable of binding TNF protein.

Claim 47. The isolated DNA molecule according to Claim 46, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 163 of FIG. 2A.

Claim 48. The isolated DNA molecule according to Claim 46, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 185 of FIG. 2A.

Claim 49. The isolated DNA molecule according to Claim 46, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 235 of FIG. 2A.

Claim 50. An isolated DNA molecule encoding a soluble TNF receptor protein selected from the group consisting of:

(a) a TNF receptor polypeptide having a sequence of amino acids comprising from amino acid 1 to amino acid 163 of FIG. 2A;

(b) a TNF receptor polypeptide having a sequence of amino acids comprising from amino acid 1 to amino acid 233 of FIG. 3A; and

(c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues,

wherein said soluble TNF receptor protein is capable of binding TNF.

Claim 51. A recombinant expression vector comprising the DNA molecule according to Claim 46, 47, 48, 49 or 50.

Claim 52. A host cell transformed or transfected with the recombinant expression vector according to Claim 51.

Claim 53. The host cell of Claim 52, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 54. The host cell of Claim 53, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 55. The host cell of Claim 54, wherein said mammalian cell is CHO cells.

Claim 56. A process for producing a protein capable of binding TNF, said process comprising culturing a host cell of Claim 52 under conditions suitable to effect expression of said protein.

Claim 57. The process of Claim 56, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 58. The process of Claim 57, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 59. The process of Claim 58, wherein said mammalian cell is CHO cells.

Claim 60. An isolated DNA molecule encoding a protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of FIG. 2A and amino acids 1-233 of FIG. 3A, wherein said protein lacks amino acids 236-265 of FIG. 2A and amino acids 234-265 of FIG. 3A, respectively, and wherein said protein is capable of binding TNF.

Claim 61. The isolated DNA molecule according to Claim 60, wherein said protein comprises amino acids 1-163 of FIG. 2A.

Claim 62. The isolated DNA molecule according to Claim 60, wherein said protein comprises amino acids 1-185 of FIG. 2A.

Claim 63. The isolated DNA molecule according to Claim 60, wherein said protein comprises amino acids 1-235 of FIG. 2A.

Claim 64. An isolated DNA molecule encoding a protein selected from the group consisting of:

(a) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-163 of FIG. 2A, wherein said polypeptide lacks amino acids 236-265 of FIG. 2A;

(b) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-233 of FIG. 3A, wherein said

polypeptide lacks amino acids 234-265 of FIG. 3A; and

(c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues,

wherein said protein is capable of binding TNF.

Claim 65. A recombinant expression vector comprising the DNA molecule according to Claim 60, 61, 62, 63 or 64.

Claim 66. A host cell transformed or transfected with the recombinant expression vector according to Claim 65.

Claim 67. The host cell of Claim 66, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 68. The host cell of Claim 67, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 69. The host cell of Claim 68, wherein said mammalian cell is CHO cells.

Claim 70. A process for producing a protein capable of binding TNF, said process comprising culturing a host cell of Claim 67 under conditions suitable to effect expression of said protein.

Claim 71. The process of Claim 70, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 72. The process of Claim 71, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 73. The process of Claim 72, wherein said mammalian cell is CHO cells.

Claim 74. An isolated DNA molecule encoding a protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of FIG. 2A and amino acids 1-233 of FIG. 3A, wherein said protein lacks a functional transmembrane region, and wherein said protein is capable of binding TNF.

Claim 75. The isolated DNA molecule according to Claim 74, wherein said protein comprises amino acids 1-163 of FIG. 2A.

Claim 76. The isolated DNA molecule according to Claim 74, wherein said protein comprises amino acids 1-185 of FIG. 2A.

Claim 77. The isolated DNA molecule according to Claim 74, wherein said protein comprises amino acids 1-235 of FIG. 2A.

Claim 78. An isolated DNA molecule encoding a protein selected from the group consisting of:

(a) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-163 of FIG. 2A;

(b) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-233 of FIG. 3A; and

(c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues,

wherein said protein lacks a functional transmembrane region; and wherein said protein is capable of binding TNF.

Claim 79. A recombinant expression vector comprising the DNA molecule according to Claim 74, 75, 76, 77 or 78.

Claim 80. A host cell transformed or transfected with the recombinant expression vector according to Claim 79.

Claim 81. The host cell of Claim 80, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 82. The host cell of Claim 81, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 83. The host cell of Claim 82, wherein said mammalian cell is CHO cells.

Claim 84. A process for producing a protein capable of binding TNF, said process comprising culturing a host cell of Claim 80 under conditions suitable to effect expression of said protein.

Claim 85. The process of Claim 84, wherein said host cell is selected from the group consisting of a microbial cell and a mammalian cell.

Claim 86. The process of Claim 85, wherein said mammalian cell is selected from the group consisting of L cells, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells.

Claim 87. The process of Claim 86, wherein said mammalian cell is CHO cells.

ABSTRACT OF THE DISCLOSURE

Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.

Kept GKH

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
09/144,502	08/31/98	SMITH C	A-7210

0242/0929

SUGHRUE MION ZINN MACPEAK & SEAS
2100 PENNSYLVANIA AVENUE NW
WASHINGTON DC 20037-3202

NOT ASSIGNED

1646

DATE MAILED: 09/29/98

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- [X] 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- [ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- [ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- [ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- [ ] 7. OTHER: _____

APPLICANT MUST PROVIDE:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- [X] An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- [ ] For Rules Interpretation, call (703) 308-1123.
- [ ] For CRF submission help, call (703) 308-4212.
- [ ] For PatentIn software help, call (703) 308-6856.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

FORM PTO-1661 (REV.9-97)

Figure 1


HuTNF-R
HuTNF-RΔ235
HuTNF-RΔ185
HuTNF-RΔ163
HuTNF-RΔ142
MuTNF-R

Figure 2A

```
                                                GCGAGGCAGGCAGCCTGGAGAGAAGGCG        28

CTGGGCTGCGAGGGCGCGAGGGCGCGAGGGCAGGGGGCAACCGGACCCCGCCCCGCATCC        87

ATG GCG CCC GTC GCC GTC TGG GCC GCG CTG GCC GTC GGA CTG GAG          132
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu          -2

CTC TGG GCT GCG GCG CAC GCC TTG CCC GCC CAG GTG GCA TTT ACA          177
Leu Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr           8

CCC TAC GCC CCG GAG CCC GGG AGC ACA TGC CGG CTC AGA GAA TAC          222
Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr          23

TAT GAC CAG ACA GCT CAG ATG TGC TGC AGC AAA TGC TCG CCG GGC          267
Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly          38

CAA CAT GCA AAA GTC TTC TGT ACC AAG ACC TCG GAC ACC GTG TGT          312
Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys          53

GAC TCC TGT GAG GAC AGC ACA TAC ACC CAG CTC TGG AAC TGG GTT          357
Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val          68

CCC GAG TGC TTG AGC TGT GGC TCC CGC TGT AGC TCT GAC CAG GTG          402
Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val          83

GAA ACT CAA GCC TGC ACT CGG GAA CAG AAC CGC ATC TGC ACC TGC          447
Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys          98

AGG CCC GGC TGG TAC TGC GCG CTG AGC AAG CAG GAG GGG TGC CGG          492
Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg          113

CTG TGC GCG CCG CTG CGC AAG TGC CGC CCG GGC TTC GGC GTG GCC          537
Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala          128

AGA CCA GGA ACT GAA ACA TCA GAC GTG GTG TGC AAG CCC TGT GCC          582
Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala          143
                                                    ↑

CCG GGG ACG TTC TCC AAC ACG ACT TCA TCC ACG GAT ATT TGC AGG          627
Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg          158

CCC CAC CAG ATC TGT AAC GTG GTG GCC ATC CCT GGG AAT GCA AGC          672
Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser          173
                    ↑

ATG GAT GCA GTC TGC ACG TCC ACG TCC CCC ACC CGG AGT ATG GCC          717
Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser Met Ala          188
                                            ↑

CCA GGG GCA GTA CAC TTA CCC CAG CCA GTG TCC ACA CGA TCC CAA          762
Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser Gln          203

CAC ACG CAG CCA ACT CCA GAA CCC AGC ACT GCT CCA AGC ACC TCC          807
His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser          218

TTC CTG CTC CCA ATG GGC CCC AGC CCC CCA GCT GAA GGG AGC ACT          852
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr          233

GGC GAC TTC GCT CTT CCA GTT GGA CTG ATT GTG GGT GTG ACA GCC          897
Gly Asp Phe Ala Leu Pro Val Gly Leu Ile Val Gly Val Thr Ala          248
         ↑

TTG GGT CTA CTA ATA ATA GGA GTG GTG AAC TGT GTC ATC ATG ACC          942
Leu Gly Leu Leu Ile Ile Gly Val Val Asn Cys Val Ile Met Thr          263
```

Figure 2B

```
CAG GTG AAA AAG AAG CCC TTG TGC CTG CAG AGA GAA GCC AAG GTG      987
Gln Val Lys Lys Lys Pro Leu Cys Leu Gln Arg Glu Ala Lys Val      278

CCT CAC TTG CCT GCC GAT AAG GCC CGG GGT ACA CAG GGC CCC GAG     1032
Pro His Leu Pro Ala Asp Lys Ala Arg Gly Thr Gln Gly Pro Glu      293

CAG CAG CAC CTG CTG ATC ACA GCG CCG AGC TCC AGC AGC AGC TCC     1077
Gln Gln His Leu Leu Ile Thr Ala Pro Ser Ser Ser Ser Ser Ser      308

CTG GAG AGC TCG GCC AGT GCG TTG GAC AGA AGG GCG CCC ACT CGG     1122
Leu Glu Ser Ser Ala Ser Ala Leu Asp Arg Arg Ala Pro Thr Arg      323

AAC CAG CCA CAG GCA CCA GGC GTG GAG GCC AGT GGG GCC GGG GAG     1167
Asn Gln Pro Gln Ala Pro Gly Val Glu Ala Ser Gly Ala Gly Glu      338

GCC CGG GCC AGC ACC GGG AGC TCA GAT TCT TCC CCT GGT GGC CAT     1212
Ala Arg Ala Ser Thr Gly Ser Ser Asp Ser Ser Pro Gly Gly His      353

GGG ACC CAG GTC AAT GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC     1257
Gly Thr Gln Val Asn Val Thr Cys Ile Val Asn Val Cys Ser Ser      368

TCT GAC CAC AGC TCA CAG TGC TCC TCC CAA GCC AGC TCC ACA ATG     1302
Ser Asp His Ser Ser Gln Cys Ser Ser Gln Ala Ser Ser Thr Met      383

GGA GAC ACA GAT TCC AGC CCC TCG GAG TCC CCG AAG GAC GAG CAG     1347
Gly Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro Lys Asp Glu Gln      398

GTC CCC TTC TCC AAG GAG GAA TGT GCC TTT CGG TCA CAG CTG GAG     1392
Val Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser Gln Leu Glu      413

ACG CCA GAG ACC CTG CTG GGG AGC ACC GAA GAG AAG CCC CTG CCC     1437
Thr Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro Leu Pro      428

CTT GGA GTG CCT GAT GCT GGG ATG AAG CCC AGT                     1470
Leu Gly Val Pro Asp Ala Gly Met Lys Pro Ser                     439

TAACCAGGCCGGTGTGGGCTGTGTCGTAGCCAAGGTGGGCTGAGCCCTGGCAGGATGAC

CCTGCGAAGGGGCCCTGGTCCTTCCAGGCCCCCACCACTAGGACTCTGAGGCTCTTTCT

GGGCCAAGTTCCTCTAGTGCCCTCCACAGCCGCAGCCTCCCTCTGACCTGCAG...
```

Figure 3A

```
                                                    CGCAGCTGAGGCACTAGAGCTCC      23

AGGCACAAGGGCGGGAGCCACCGCTGCCCCT ATG GCG CCC GCC GCC CTC TGG      75
                                 Met Ala Pro Ala Ala Leu Trp     -16

GTC GCG CTG GTC TTC GAA CTG CAG CTG TGG GCC ACC GGG CAC ACA      120
Val Ala Leu Val Phe Glu Leu Gln Leu Trp Ala Thr Gly His Thr      -1

GTG CCC GCC CAG GTT GTC TTG ACA CCC TAC AAA CCG GAA CCT GGG      165
Val Pro Ala Gln Val Val Leu Thr Pro Tyr Lys Pro Glu Pro Gly      15

TAC GAG TGC CAG ATC TCA CAG GAA TAC TAT GAC AGG AAG GCT CAG      210
Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp Arg Lys Ala Gln      30

ATG TGC TGT GCT AAG TGT CCT CCT GGC CAA TAT GTG AAA CAT TTC      255
Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val Lys His Phe      45

TGC AAC AAG ACC TCG GAC ACC GTG TGT GCG GAC TGT GAG GCA AGC      300
Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu Ala Ser      60

ATG TAT ACC CAG GTC TGG AAC CAG TTT CGT ACA TGT TTG AGC TGC      345
Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser Cys      75

AGT TCT TCC TGT ACC ACT GAC CAG GTG GAG ATC CGC GCC TGC ACT      390
Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr      90

AAA CAG CAG AAC CGA GTG TGT GCT TGC GAA GCT GGC AGG TAC TgC      435
Lys Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys      105

GCC TTG AAA ACC CAT TCT GGC AGC TGT CGA CAG TGC ATG AGG CTG      480
Ala Leu Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu      120

AGC AAG TGC GGC CCT GGC TTC GGA GTG GCC AGT TCA AGA GCC CCA      525
Ser Lys Cys Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro      135

AAT GGA AAT GTG CTA TGC AAG GCC TGT GCC CCA GGG ACG TTC TCT      570
Asn Gly Asn Val Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser      150

GAC ACC ACA TCA TCC ACT GAT GTG TGC AGG CCC CAC CGC ATC TGT      615
Asp Thr Thr Ser Ser Thr Asp Val Cys Arg Pro His Arg Ile Cys      165

AGC ATC CTG GCT ATT CCC GGA AAT GCA AGC ACA GAT GCA GTC TGT      660
Ser Ile Leu Ala Ile Pro Gly Asn Ala Ser Thr Asp Ala Val Cys      180

GCG CCC GAG TCC CCA ACT CTA AGT GCC ATC CCA AGG ACA CTC TAC      705
Ala Pro Glu Ser Pro Thr Leu Ser Ala Ile Pro Arg Thr Leu Tyr      195

GTA TCT CAG CCA GAG CCC ACA AGA TCC CAA CCC CTG GAT CAA GAG      750
Val Ser Gln Pro Glu Pro Thr Arg Ser Gln Pro Leu Asp Gln Glu      210

CCA GGG CCC AGC CAA ACT CCA AGC ATC CTT ACA TCG TTG GGT TCA      795
Pro Gly Pro Ser Gln Thr Pro Ser Ile Leu Thr Ser Leu Gly Ser      225

ACC CCC ATT ATT GAA CAA AGT ACC AAG GGT GGC ATC TCT CTT CCA      840
Thr Pro Ile Ile Glu Gln Ser Thr Lys Gly Gly Ile Ser Leu Pro      240

ATT GGT CTG ATT GTT GGA GTG ACA TCA CTG GGT CTG CTG ATG TTA      885
Ile Gly Leu Ile Val Gly Val Thr Ser Leu Gly Leu Leu Met Leu      255
```

Figure 3B

```
GGA CTG GTG AAC TGC ATC ATC CTG GTG CAG AGG AAA AAG AAG CCC     930
Gly Leu Val Asn Cys Ile Ile Leu Val Gln Arg Lys Lys Lys Pro     270

TCC TGC CTA CAA AGA GAT GCC AAG GTG CCT CAT GTG CCT GAT GAG     975
Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val Pro Asp Glu     285

AAA TCC CAG GAT GCA GTA GGC CTT GAG CAG CAG CAC CTG TTG ACC    1020
Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu Leu Thr     300

ACC GCA CCC AGT TCC AGC AGC AGC TCC CTA GAG AGC TCA GCC AGC    1065
Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser     315

GCT GGG GAC CGA AGG GCG CCC CCT GGG GGC CAT CCC CAA GCA AGA    1110
Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg     330

GTC ATG GCG GAG GCC CAA GGG TTT CAG GAG GCC CGT GCC AGC TCC    1155
Val Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser     345

AGG ATT TCA GAT TCT TCC CAC GGA AGC CAC GGG ACC CAC GTC AAC    1200
Arg Ile Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn     360

GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC TCT GAC CAC AGT TCT    1245
Val Thr Cys Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser     375

CAG TGC TCT TCC CAA GCC AGC GCC ACA GTG GGA GAC CCA GAT GCC    1290
Gln Cys Ser Ser Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala     390

AAG CCC TCA GCG TCC CCA AAG GAT GAG CAG GTC CCC TTC TCT CAG    1335
Lys Pro Ser Ala Ser Pro Lys Asp Glu Gln Val Pro Phe Ser Gln     405

GAG GAG TGT CCG TCT CAG TCC CCG TGT GAG ACT ACA GAG ACA CTG    1380
Glu Glu Cys Pro Ser Gln Ser Pro Cys Glu Thr Thr Glu Thr Leu     420

CAG AGC CAT GAG AAG CCC TTG CCC CTT GGT GTG CCG GAT ATG GGC    1425
Gln Ser His Glu Lys Pro Leu Pro Leu Gly Val Pro Asp Met Gly     435

ATG AAG CCC AGC CAA GCT GGC TGG TTT GAT CAG ATT GCA GTC AAA    1470
Met Lys Pro Ser Gln Ala Gly Trp Phe Asp Gln Ile Ala Val Lys     450

GTG GCC                                                       1476
Val Ala                                                        452


TGACCCCTGACAGGGGTAACACCCTGCAAAGGGACCCCCGAGACCCTGAACCCATGGAAC  1536
TTCATGACTTTTGCTGGATCCATTTCCCTTAGTGGCTTCCAGAGCCCCAGTTGCAGGTCA  1596
AGTGAGGGCTGAGACAGCTAGAGTGGTCAAAAACTGCCATGGTGTTTTATGGGGGCAGTC  1656
CCAGGAAGTTGTTGCTCTTCCATGACCCCTCTGGATCTCCTGGGCTCTTGCCTGATTCTT  1716
GCTTCTGAGAGGCCCCAGTATTTTTTCCTTCTAAGGAGCTAACATCCTCTTCCATGAATA  1776
GCACAGCTCTTCAGCCTGAATGCTGACACTGCAGGGCGGTTCCAGCAAGTAGGAGCAAGT  1836
GGTGGCCTGGTAGGGCACAGAGGCCCTTCAGGTTAGTGCTAAACTCTTAGGAAGTACCCT  1896
CTCCAAGCCCACCGAAATTCTTTTGATGCAAGAATCAGAGGCCCCATCAGGCAGAGTTGC  1956
TCTGTTATAGGATGGTAGGGCTGTAACTCAgTGGTCCAgTGTGCTTTTAGCATGCCCTGG  2016
GTTTGATCCTCAGCAACACATGCAAAACGTAAGTAGACAGCAGACAGCAGACAGCACAGC  2076
CAGCCCCCTGTGTGGTTTGCAGCCTCTGCCTTTGACTTTTACTCTGGTGGGCACACAGAG  2136
GGCTGGAGCTCCTCCTCCTGACCTTCTAATGAGCCCTTCCAAGGCCACGCCTTCCTTCAG  2196
GGAATCTCAGGGACTGTAGAGTTCCCAGGCCCCTGCAGCCACCTGTCTCTTCCTACCTCA  2256
GCCTGGAGCAcTCCCTCTAACTCCCCAACGgCTTGGTACTGTACTTGCTGTGACCCCAAC  2316
GTGCATTGTCCGGGTTAGGCACTGTGAGTTGGAACAGCTcATGACATCGGTTGAAAGGCC  2376
CACCCGGAAACAGCTAAGCCAGCTCTTTTGCCAAAGGATTCATGCCGGTTTTCTAATCAa  2436
CCTGCTCCCTAGCATTGCCTGGAAGGAAAGGGTTCAGGAGACTCCTCAAGAAGCAAGTTC  2496
AGTCTCAGGTGCTTGGATGCCATGCTCACCGATTCCACTGGATATGAACTTGGCAGAGGA  2556
```

Figure 3C

```
GCCTAGTTGTTGCCATGGAGACTTAAAGAGCTCAGCACTCTGGAATCAAGATACTGGACA  2616
CTTGGGGCCGACTTGTTAAGGCTCTGCAGCATCAGACTGTAGAGGGGAAGGAACACGTCT  2676
GCCCCCTGGTGGCCCGTCCTGGGAtGACCTCGGGCCtCCTAGGCAACAAAAGAATGAATT  2736
GGAAAGGATGTTCCTGGGTGTGGCCTAGCTCCTGTGCTTGTGTGGATCCCTAAAGGGTGT  2796
GCTAAGGAGCAATTGCACTGTGTGCTGGACAGAATTCCTGCTTATAAATGCTTTTTGTTG  2856
TTGTTTTGTACACTGAGCCCTGGCTGAGCCACCCCACCCCACCTCCCATCCCACCTTTAC  2916
ACGCCACTCTTGCATGAGAACCTGGCTGTCTCCCACTTGTAGCCTGTGGATGCTGAGGAA  2976
ACACCCAGCCAAGTAGACTCCAGGCTTgCCCCTATCTCCTGcTaTGAGTcTggCCTCCTC  3036
AtTgTGTTGTGGGAAgGAGACGGGtTCTGTCATCTCGGAAcgCCCACACCGTGGATGTGA  3096
ACAaTGGCTGTACTAGCTTAGACCAgCTTAGGGCTCTGCATATCACAGGAGGGGGAGCAG  3156
GGAACAATTTGAGTGCTGACCTATAACACAgTTCCTAAAGGATCGGGCAGTCCAGAATCT  3216
CCTCCTTCAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCCATGTT      3276
TGCATGTATGTGTGTGCCAGTGTGTGGAGGCCCGAGGTTGGCTTTGGGTGTGTTTGATCA  3336
CTCTCCAGTTACTGAGGCGGGCTCTCATCTGTACCCAGAGCTTGCACATTTTCTAGTCTA  3396
ACTTGATTCAGGGATCTCTGTCTGCCTATGGAGgTGCTCAGGTTACAGGCAGGCTGCCAT  3456
ACCTGCCCGACATTTACATGAATACTAGAGATCTGAATTCTGGTCCTCACACTTGTATAC  3516
CTGCATTTTATCCACTAAGACATCTCTCCAAGGGCTCCCCCTTCCTATTTAATAAGTTAG  3576
TTTTGAACTGGCAAGATGGCTCAGTGGGTAAGGCAGTTTGCGGACAAACCTGATGACCTG  3636
AGTTGGATCCCTGACCATAAGGTAGAAGAGACCTGATTCCTGCAAGTTGTCCTCTGACCA  3696
CCACCCCATACATGCTTCTGCATATGTGCACACATCACATTCTTGCACACACACTCACAT  3756
ACCATAAATGTAATAAATTTTTTTAAATAAATTGATTTTATCTTTTAAAAAAAAAAA     3813
```

Kept by G.Kit Immunex

PTO-103X
(Rev. 8-95)

FILING RECEIPT

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/144,502	08/31/98	1646	$3,084.00	A-7210	6	87	17

SUGHRUE MION ZINN MACPEAK & SEAS
2100 PENNSYLVANIA AVENUE NW
WASHINGTON DC 20037-3202

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

CRAIG A. SMITH, SEATTLE, WA; RAYMOND G. GOODWIN, SEATTLE, WA; M. PATRICIA BECKMANN, POULSBO, WA.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A RE OF	08/346,555	11/29/94	PAT	5,712,155
WHICH IS A CON OF	07/523,635	05/10/90	PAT	5,395,760
WHICH IS A CIP OF	07/421,417	10/13/89	ABN	
WHICH IS A CIP OF	07/405,370	09/11/89	ABN	
WHICH IS A CIP OF	07/403,241	09/05/89	ABN	

FOREIGN FILING LICENSE GRANTED 09/24/98

TITLE

DNA ENCODING TUMOR NECROSIS FACTOR-ALPHA AND -BETA RECEPTORS

PRELIMINARY CLASS: 435

(see reverse)

PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re Application of:

CRAIG A. SMITH et al

Appln. No.: **09/144,502** Group Art Unit: **1646**

Filed: **August 31, 1998** Examiner: **Fitzgerald, D.**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

PAPERS ENTITLED:

(1) **NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES;**

(2) **PRELIMINARY AMENDMENT**; and

(3) **STATEMENT IN SUPPORT OF SUBMISSION** (accompanied by Sequence Listing and DOS Version diskette containing same).

SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
(202) 293-7060

DOCKET NO.: **LY-7210**
ATTORNEY: **GK/vf**

Date: October 9, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CRAIG A. SMITH et al

Appln. No.: **09/144,502** Group Art Unit: **1646**

Filed: **August 31, 1998** Examiner: **Fitzgerald, D.**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

PRELIMINARY AMENDMENT

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

Prior to examining the above-identified reissue application, please amend the application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 4, lines 17-28, delete in their entirety.

Page 5, line 25, change "Figure 2A" to -- SEQ ID NO:1 --.

Page 6, line 6, change "Figure 2A" to -- SEQ ID NO:1 --; and

line 11, change "Figure 2A" to -- SEQ ID NO:1 --.

Page 8, lines 27-28, change "Figures 2-3 or Figures 4-6" to -- SEQ ID NO:1 or SEQ ID NO:3 --.

Page 9, line 23, change "clone 11" to -- clone 1 --;

line 25, change "clone 11" to -- clone 1 --; and

line 26, change "Figures 4-6" to -- SEQ ID NO:1 --.

Page 13, line 21, change "Figure 2A" to -- SEQ ID NO:1 --;

line 23, change "transmembrane" to -- extracellular --;

line 25, change "Figure 2A" to -- SEQ ID NO:1 --; and

line 26, change "Figure 2A" to -- SEQ ID NO:1 --.

Page 15, line 13, change "Figure 2A" to -- SEQ ID NO:1 --.

Page 30, line 24, change "Figure 2A" to -- SEQ ID NO:1 --; and

line 28, after "oligonucleotides", insert -- (encoding amino acids corresponding to Ala^{229}-Asp^{235} of SEQ ID NO:1) --.

Page 31, line 18, change "Figure 2A" to -- SEQ ID NO:1 --; and

line 22, after "linkers", insert -- (encoding amino acids corresponding to Ile^{162}-Ala^{176} and Val^{177}-Arg^{185} of SEQ ID NO:1) --.

Page 32, line 10, change "Figure 2A" to -- SEQ ID NO:1 --;

line 12, after "linkers", insert -- (encoding amino acids corresponding to Ile^{162}-Cys^{163} of SEQ ID NO:1) --; and

line 32, change "Figure 2A" to -- SEQ ID NO:1 --.

Page 33, line 2, after "linker", insert -- (encoding amino acids corresponding to Thr^{132}-Cys^{142} of SEQ ID NO:1) --.

Page 36, line 2, after "primers", insert -- (encoding amino acids corresponding in part to amino acids Leu^{1}-Thr^{8} and Pro^{225}-Asp^{235} of SEQ ID NO:1) --.

Page 38, line 29, change "Figures 3A-3B" to -- SEQ ID NO:3 and SEQ ID NO:4 --.

Page 40, after line 2, insert

-- **DETAILED DESCRIPTION OF THE SEQUENCE LISTING**

SEQ ID NO:1 and SEQ ID NO:2 show the partial cDNA sequence and derived amino acid sequence of the human TNF-R clone 1. Nucleotides are numbered from the beginning of the 5' untranslated region. Amino acids are numbered from the beginning of the signal peptide sequence. The putative signal sequence is represented by amino acid -22 to -1. The N-terminus of the mature TNF-R begins with amino acid 1. The predicted transmembrane region extends from amino acids 236-265.

SEQ ID NO:3 and SEQ ID NO:4 show the cDNA sequence and derived amino acid sequence of murine TNF-R clone 11. The putative signal peptide sequence is represented by amino acids -22 to -1. The N-terminus of the mature TNF-R protein begins with amino acid 1. The predicted transmembrane region extends from amino acids 234 to 265. --

Pages 41-53, please renumber as new pages 54-66, respectively.

IN THE SEQUENCE LISTING:

Please insert the Sequence Listing (i.e., new pages 41-53) being filed simultaneously herewith.

IN THE DRAWINGS:

Please delete Figures 2A-2B and 3A-3C (in their entirety).

REMARKS

The amendments to the specification were made in order for the present application to be consistent with Parent Application Serial No. 07/523,635, filed November 29, 1994 (now U.S. Patent No. 5,395,760)[1/]; and to correct obvious typographical errors therein.

The Sequence Listing, filed simultaneously herewith, is being submitted and the specification is also being amended to be consistent with the amendments made in related Application Serial No. 08/650,000, filed June 9, 1998 (now allowed).

Also, the deletion of Figures 2-3 (in their entirety) and insertion of SEQ ID NOs:1-4 therein is made in order for the Sequence Listing and drawings to be consistent with related Application Serial No. 08/650,000, filed June 9, 1998 (now allowed).

Hence, the amendments to the specification, the insertion of the Sequence Listing and deletion of Figures 2-3 do not constitute new matter, and thus entry is requested.

[1/] Note, due to a printing error, column 6, line 55, of U.S. Patent 5,395,760 refers to "Figures 2A-2C", rather than "Figures 2A-2B".

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
(202) 293-7060

Date: October 9, 1998

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CRAIG A. SMITH et al

Appln. No.: **09/144,502** Group Art Unit: **1646**

Filed: **August 31, 1998** Examiner: **Fitzgerald, D.**

For: **DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS**

STATEMENT IN SUPPORT OF SUBMISSION IN ACCORDANCE WITH FORMER 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

The following statement is provided to meet the requirements of Former 37 C.F.R. §§ 1.821-1.825.

I hereby state that the content of the computer readable copy of the Sequence Listing submitted in accordance with Former 37 C.F.R. §§ 1.821-1.825, respectively, is the same as the Sequence Listing filed simultaneously herewith.

The Examiner is requested to note that the Sequence Listing being filed herewith is submitted under Former 37 C.F.R. §§ 1.821-1.825, as the present application is a reissue application of U.S. Patent No. 5,712,155 which issued January 27, 1998, based on U.S. Patent Application No. 08/346,555, filed November 29, 1994, i.e., prior to the effective new rules dated of July 1, 1998 (see 63 *Federal Register* 29620).

STATEMENT IN SUPPORT OF SUBMISSION IN ACCORDANCE WITH FORMER 37 C.F.R. §§ 1.821-1.825
U.S. Appln. No. 09/144,502

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge and that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

10/9/98
Date

Gordon Kit

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: SMITH, Craig A.
GOODWIN, Raymond G.
BECKMANN, M. Patricia

(ii) TITLE OF INVENTION: DNA ENCODING TUMOR NECROSIS FACTOR-α AND -β RECEPTORS

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: IMMUNEX CORPORATION
(B) STREET: 51 University Street
(C) CITY: Seattle
(D) STATE: WASHINGTON
(E) COUNTRY: U.S.A.
(F) ZIP: 98101

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 09/144,502
(B) FILING DATE: 31-AUG-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/346,555
(B) FILING DATE: 29-NOV-1994

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/523,635
(B) FILING DATE: 10-MAY-1990

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/421,417
(B) FILING DATE: 13-OCT-1989

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/405,370
(B) FILING DATE: 11-SEPT-1989

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/403,241
(B) FILING DATE: 05-SEPT-1989

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: KIT, Gordon
(B) REGISTRATION NUMBER: 30,764
(C) REFERENCE/DOCKET NUMBER: A-7210

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 293-7060
(B) TELEFAX: (202) 293-7860

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1641 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(G) CELL TYPE: Fibroblast
(H) CELL LINE: WI-26 VA4

(vii) IMMEDIATE SOURCE:
(A) LIBRARY: WI-26 VA4
(B) CLONE: 1

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 88..1473

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 154..1470

(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: 88..153

(x) PUBLICATION INFORMATION:
(A) AUTHORS: Smith, Craig A.
Davis, Terri
Anderson, Dirk
Solam, Lisabeth
Beckmann, M. P.
Jerzy, Rita
Dower, Steven K.
Cosman, David
Goodwin, Raymond G.

(B) TITLE: A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins
(C) JOURNAL: Science
(D) VOLUME: 248
(F) PAGES: 1019-1023
(G) DATE: 25-MAY-1990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GCGAGGCAGG CAGCCTGGAG AGAAGGCGCT GGGCTGCGAG GGCGCGAGGG CGCGAGGGCA      60

GGGGGCAACC GGACCCCGCC CGCATCC ATG GCG CCC GTC GCC GTC TGG GCC          111
                                Met Ala Pro Val Ala Val Trp Ala
                               -22     -20                 -15

GCG CTG GCC GTC GGA CTG GAG CTC TGG GCT GCG GCG CAC GCC TTG CCC       159
Ala Leu Ala Val Gly Leu Glu Leu Trp Ala Ala Ala His Ala Leu Pro
               -10                 -5                  1

GCC CAG GTG GCA TTT ACA CCC TAC GCC CCG GAG CCC GGG AGC ACA TGC       207
Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys
          5                  10                  15

CGG CTC AGA GAA TAC TAT GAC CAG ACA GCT CAG ATG TGC TGC AGC AAA       255
Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys
     20                  25                  30

TGC TCG CCG GGC CAA CAT GCA AAA GTC TTC TGT ACC AAG ACC TCG GAC       303
Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp
 35                  40                  45                  50

ACC GTG TGT GAC TCC TGT GAG GAC AGC ACA TAC ACC CAG CTC TGG AAC       351
Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn
                55                  60                  65

TGG GTT CCC GAG TGC TTG AGC TGT GGC TCC CGC TGT AGC TCT GAC CAG       399
Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln
            70                  75                  80

GTG GAA ACT CAA GCC TGC ACT CGG GAA CAG AAC CGC ATC TGC ACC TGC       447
Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys
         85                  90                  95

AGG CCC GGC TGG TAC TGC GCG CTG AGC AAG CAG GAG GGG TGC CGG CTG       495
Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu
    100                 105                 110

TGC GCG CCG CTG CGC AAG TGC CGC CCG GGC TTC GGC GTG GCC AGA CCA       543
Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala Arg Pro
115                 120                 125                 130

GGA ACT GAA ACA TCA GAC GTG GTG TGC AAG CCC TGT GCC CCG GGG ACG       591
Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr
               135                 140                 145
```

```
TTC TCC AAC ACG ACT TCA TCC ACG GAT ATT TGC AGG CCC CAC CAG ATC        639
Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile
            150                 155                 160

TGT AAC GTG GTG GCC ATC CCT GGG AAT GCA AGC ATG GAT GCA GTC TGC        687
Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys
        165                 170                 175

ACG TCC ACG TCC CCC ACC CGG AGT ATG GCC CCA GGG GCA GTA CAC TTA        735
Thr Ser Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu
    180                 185                 190

CCC CAG CCA GTG TCC ACA CGA TCC CAA CAC ACG CAG CCA ACT CCA GAA        783
Pro Gln Pro Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu
195                 200                 205                 210

CCC AGC ACT GCT CCA AGC ACC TCC TTC CTG CTC CCA ATG GGC CCC AGC        831
Pro Ser Thr Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser
                215                 220                 225

CCC CCA GCT GAA GGG AGC ACT GGC GAC TTC GCT CTT CCA GTT GGA CTG        879
Pro Pro Ala Glu Gly Ser Thr Gly Asp Phe Ala Leu Pro Val Gly Leu
            230                 235                 240

ATT GTG GGT GTG ACA GCC TTG GGT CTA CTA ATA ATA GGA GTG GTG AAC        927
Ile Val Gly Val Thr Ala Leu Gly Leu Leu Ile Ile Gly Val Val Asn
        245                 250                 255

TGT GTC ATC ATG ACC CAG GTG AAA AAG AAG CCC TTG TGC CTG CAG AGA        975
Cys Val Ile Met Thr Gln Val Lys Lys Lys Pro Leu Cys Leu Gln Arg
    260                 265                 270

GAA GCC AAG GTG CCT CAC TTG CCT GCC GAT AAG GCC CGG GGT ACA CAG       1023
Glu Ala Lys Val Pro His Leu Pro Ala Asp Lys Ala Arg Gly Thr Gln
275                 280                 285                 290

GGC CCC GAG CAG CAG CAC CTG CTG ATC ACA GCG CCG AGC TCC AGC AGC       1071
Gly Pro Glu Gln Gln His Leu Leu Ile Thr Ala Pro Ser Ser Ser Ser
                295                 300                 305

AGC TCC CTG GAG AGC TCG GCC AGT GCG TTG GAC AGA AGG GCG CCC ACT       1119
Ser Ser Leu Glu Ser Ser Ala Ser Ala Leu Asp Arg Arg Ala Pro Thr
            310                 315                 320

CGG AAC CAG CCA CAG GCA CCA GGC GTG GAG GCC AGT GGG GCC GGG GAG       1167
Arg Asn Gln Pro Gln Ala Pro Gly Val Glu Ala Ser Gly Ala Gly Glu
        325                 330                 335

GCC CGG GCC AGC ACC GGG AGC TCA GAT TCT TCC CCT GGT GGC CAT GGG       1215
Ala Arg Ala Ser Thr Gly Ser Ser Asp Ser Ser Pro Gly Gly His Gly
    340                 345                 350

ACC CAG GTC AAT GTC ACC TGC ATC GTG AAC GTC TGT AGC AGC TCT GAC       1263
Thr Gln Val Asn Val Thr Cys Ile Val Asn Val Cys Ser Ser Ser Asp
355                 360                 365                 370
```

```
CAC AGC TCA CAG TGC TCC TCC CAA GCC AGC TCC ACA ATG GGA GAC ACA      1311
His Ser Ser Gln Cys Ser Ser Gln Ala Ser Ser Thr Met Gly Asp Thr
                375                 380                 385

GAT TCC AGC CCC TCG GAG TCC CCG AAG GAC GAG CAG GTC CCC TTC TCC      1359
Asp Ser Ser Pro Ser Glu Ser Pro Lys Asp Glu Gln Val Pro Phe Ser
            390                 395                 400

AAG GAG GAA TGT GCC TTT CGG TCA CAG CTG GAG ACG CCA GAG ACC CTG      1407
Lys Glu Glu Cys Ala Phe Arg Ser Gln Leu Glu Thr Pro Glu Thr Leu
        405                 410                 415

CTG GGG AGC ACC GAA GAG AAG CCC CTG CCC CTT GGA GTG CCT GAT GCT      1455
Leu Gly Ser Thr Glu Glu Lys Pro Leu Pro Leu Gly Val Pro Asp Ala
    420                 425                 430

GGG ATG AAG CCC AGT TAACCAGGCC GGTGTGGGCT GTGTCGTAGC CAAGGTGGGC      1510
Gly Met Lys Pro Ser
435                 440

TGAGCCCTGG CAGGATGACC CTGCGAAGGG GCCCTGGTCC TTCCAGGCCC CCACCACTAG    1570

GACTCTGAGG CTCTTTCTGG GCCAAGTTCC TCTAGTGCCC TCCACAGCCG CAGCCTCCCT    1630

CTGACCTGCA G                                                        1641
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
-22     -20                 -15                 -10

Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
     -5                  1                   5                  10

Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
                15                  20                  25

Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
            30                  35                  40

Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
        45                  50                  55

Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
    60                  65                  70
```

```
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
 75                  80                  85                  90

Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
                95                 100                 105

Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
            110                 115                 120

Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
        125                 130                 135

Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
    140                 145                 150

Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
155                 160                 165                 170

Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
                175                 180                 185

Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
            190                 195                 200

Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
        205                 210                 215

Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly
    220                 225                 230

Asp Phe Ala Leu Pro Val Gly Leu Ile Val Gly Val Thr Ala Leu Gly
235                 240                 245                 250

Leu Leu Ile Ile Gly Val Val Asn Cys Val Ile Met Thr Gln Val Lys
                255                 260                 265

Lys Lys Pro Leu Cys Leu Gln Arg Glu Ala Lys Val Pro His Leu Pro
            270                 275                 280

Ala Asp Lys Ala Arg Gly Thr Gln Gly Pro Glu Gln Gln His Leu Leu
        285                 290                 295

Ile Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser
    300                 305                 310

Ala Leu Asp Arg Arg Ala Pro Thr Arg Asn Gln Pro Gln Ala Pro Gly
315                 320                 325                 330

Val Glu Ala Ser Gly Ala Gly Glu Ala Arg Ala Ser Thr Gly Ser Ser
                335                 340                 345

Asp Ser Ser Pro Gly Gly His Gly Thr Gln Val Asn Val Thr Cys Ile
            350                 355                 360
```

```
Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser Ser Gln
        365                 370                 375

Ala Ser Ser Thr Met Gly Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro
    380                 385                 390

Lys Asp Glu Gln Val Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser
395                 400                 405                 410

Gln Leu Glu Thr Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro
                415                 420                 425

Leu Pro Leu Gly Val Pro Asp Ala Gly Met Lys Pro Ser
            430                 435
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 3813 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
- (A) ORGANISM: mouse
- (B) STRAIN: C57BL/6
- (G) CELL TYPE: T-helper cell
- (H) CELL LINE: 7B9

(vii) IMMEDIATE SOURCE:
- (B) CLONE: 11

(ix) FEATURE:
- (A) NAME/KEY: CDS
- (B) LOCATION: 55..1479

(ix) FEATURE:
- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 121..1476

(ix) FEATURE:
- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 55..120

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CGCAGCTGAG GCACTAGAGC TCCAGGCACA AGGGCGGGAG CCACCGCTGC CCCT ATG          57
                                                             Met
                                                             -22

GCG CCC GCC GCC CTC TGG GTC GCG CTG GTC TTC GAA CTG CAG CTG TGG          105
Ala Pro Ala Ala Leu Trp Val Ala Leu Val Phe Glu Leu Gln Leu Trp
    -20                 -15                 -10

GCC ACC GGG CAC ACA GTG CCC GCC CAG GTT GTC TTG ACA CCC TAC AAA          153
Ala Thr Gly His Thr Val Pro Ala Gln Val Val Leu Thr Pro Tyr Lys
 -5                  1                   5                  10

CCG GAA CCT GGG TAC GAG TGC CAG ATC TCA CAG GAA TAC TAT GAC AGG          201
Pro Glu Pro Gly Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp Arg
            15                  20                  25

AAG GCT CAG ATG TGC TGT GCT AAG TGT CCT CCT GGC CAA TAT GTG AAA          249
Lys Ala Gln Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val Lys
        30                  35                  40

CAT TTC TGC AAC AAG ACC TCG GAC ACC GTG TGT GCG GAC TGT GAG GCA          297
His Phe Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu Ala
    45                  50                  55

AGC ATG TAT ACC CAG GTC TGG AAC CAG TTT CGT ACA TGT TTG AGC TGC          345
Ser Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser Cys
60                  65                  70                  75

AGT TCT TCC TGT ACC ACT GAC CAG GTG GAG ATC CGC GCC TGC ACT AAA          393
Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr Lys
                80                  85                  90

CAG CAG AAC CGA GTG TGT GCT TGC GAA GCT GGC AGG TAC TGC GCC TTG          441
Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys Ala Leu
            95                  100                 105

AAA ACC CAT TCT GGC AGC TGT CGA CAG TGC ATG AGG CTG AGC AAG TGC          489
Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu Ser Lys Cys
        110                 115                 120

GGC CCT GGC TTC GGA GTG GCC AGT TCA AGA GCC CCA AAT GGA AAT GTG          537
Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro Asn Gly Asn Val
    125                 130                 135

CTA TGC AAG GCC TGT GCC CCA GGG ACG TTC TCT GAC ACC ACA TCA TCC          585
Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser Asp Thr Thr Ser Ser
140                 145                 150                 155

ACT GAT GTG TGC AGG CCC CAC CGC ATC TGT AGC ATC CTG GCT ATT CCC          633
Thr Asp Val Cys Arg Pro His Arg Ile Cys Ser Ile Leu Ala Ile Pro
                160                 165                 170
```

```
GGA AAT GCA AGC ACA GAT GCA GTC TGT GCG CCC GAG TCC CCA ACT CTA          681
Gly Asn Ala Ser Thr Asp Ala Val Cys Ala Pro Glu Ser Pro Thr Leu
            175                 180                 185

AGT GCC ATC CCA AGG ACA CTC TAC GTA TCT CAG CCA GAG CCC ACA AGA          729
Ser Ala Ile Pro Arg Thr Leu Tyr Val Ser Gln Pro Glu Pro Thr Arg
        190                 195                 200

TCC CAA CCC CTG GAT CAA GAG CCA GGG CCC AGC CAA ACT CCA AGC ATC          777
Ser Gln Pro Leu Asp Gln Glu Pro Gly Pro Ser Gln Thr Pro Ser Ile
    205                 210                 215

CTT ACA TCG TTG GGT TCA ACC CCC ATT ATT GAA CAA AGT ACC AAG GGT          825
Leu Thr Ser Leu Gly Ser Thr Pro Ile Ile Glu Gln Ser Thr Lys Gly
220                 225                 230                 235

GGC ATC TCT CTT CCA ATT GGT CTG ATT GTT GGA GTG ACA TCA CTG GGT          873
Gly Ile Ser Leu Pro Ile Gly Leu Ile Val Gly Val Thr Ser Leu Gly
                240                 245                 250

CTG CTG ATG TTA GGA CTG GTG AAC TGC ATC ATC CTG GTG CAG AGG AAA          921
Leu Leu Met Leu Gly Leu Val Asn Cys Ile Ile Leu Val Gln Arg Lys
            255                 260                 265

AAG AAG CCC TCC TGC CTA CAA AGA GAT GCC AAG GTG CCT CAT GTG CCT          969
Lys Lys Pro Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val Pro
        270                 275                 280

GAT GAG AAA TCC CAG GAT GCA GTA GGC CTT GAG CAG CAG CAC CTG TTG         1017
Asp Glu Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu Leu
    285                 290                 295

ACC ACA GCA CCC AGT TCC AGC AGC AGC TCC CTA GAG AGC TCA GCC AGC         1065
Thr Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser
300                 305                 310                 315

GCT GGG GAC CGA AGG GCG CCC CCT GGG GGC CAT CCC CAA GCA AGA GTC         1113
Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg Val
                320                 325                 330

ATG GCG GAG GCC CAA GGG TTT CAG GAG GCC CGT GCC AGC TCC AGG ATT         1161
Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser Arg Ile
            335                 340                 345

TCA GAT TCT TCC CAC GGA AGC CAC GGG ACC CAC GTC AAC GTC ACC TGC         1209
Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn Val Thr Cys
        350                 355                 360

ATC GTG AAC GTC TGT AGC AGC TCT GAC CAC AGT TCT CAG TGC TCT TCC         1257
Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser Ser
    365                 370                 375

CAA GCC AGC GCC ACA GTG GGA GAC CCA GAT GCC AAG CCC TCA GCG TCC         1305
Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala Lys Pro Ser Ala Ser
380                 385                 390                 395
```

```
CCA AAG GAT GAG CAG GTC CCC TTC TCT CAG GAG GAG TGT CCG TCT CAG      1353
Pro Lys Asp Glu Gln Val Pro Phe Ser Gln Glu Glu Cys Pro Ser Gln
                400                 405                 410

TCC CCG TGT GAG ACT ACA GAG ACA CTG CAG AGC CAT GAG AAG CCC TTG      1401
Ser Pro Cys Glu Thr Thr Glu Thr Leu Gln Ser His Glu Lys Pro Leu
            415                 420                 425

CCC CTT GGT GTG CCG GAT ATG GGC ATG AAG CCC AGC CAA GCT GGC TGG      1449
Pro Leu Gly Val Pro Asp Met Gly Met Lys Pro Ser Gln Ala Gly Trp
        430                 435                 440

TTT GAT CAG ATT GCA GTC AAA GTG GCC TGACCCCTGA CAGGGGTAAC            1496
Phe Asp Gln Ile Ala Val Lys Val Ala
    445                 450

ACCCTGCAAA GGGACCCCCG AGACCCTGAA CCCATGGAAC TTCATGACTT TTGCTGGATC    1556

CATTTCCCTT AGTGGCTTCC AGAGCCCCAG TTGCAGGTCA AGTGAGGGCT GAGACAGCTA    1616

GAGTGGTCAA AAACTGCCAT GGTGTTTTAT GGGGGCAGTC CCAGGAAGTT GTTGCTCTTC    1676

CATGACCCCT CTGGATCTCC TGGGCTCTTG CCTGATTCTT GCTTCTGAGA GGCCCCAGTA    1736

TTTTTTCCTT CTAAGGAGCT AACATCCTCT TCCATGAATA GCACAGCTCT TCAGCCTGAA    1796

TGCTGACACT GCAGGGCGGT TCCAGCAAGT AGGAGCAAGT GGTGGCCTGG TAGGGCACAG    1856

AGGCCCTTCA GGTTAGTGCT AAACTCTTAG GAAGTACCCT CTCCAAGCCC ACCGAAATTC    1916

TTTTGATGCA AGAATCAGAG GCCCCATCAG GCAGAGTTGC TCTGTTATAG GATGGTAGGG    1976

CTGTAACTCA GTGGTCCAGT GTGCTTTTAG CATGCCCTGG GTTTGATCCT CAGCAACACA    2036

TGCAAAACGT AAGTAGACAG CAGACAGCAG ACAGCACAGC CAGCCCCCTG TGTGGTTTGC    2096

AGCCTCTGCC TTTGACTTTT ACTCTGGTGG GCACACAGAG GGCTGGAGCT CCTCCTCCTG    2156

ACCTTCTAAT GAGCCCTTCC AAGGCCACGC CTTCCTTCAG GGAATCTCAG GGACTGTAGA    2216

GTTCCCAGGC CCCTGCAGCC ACCTGTCTCT TCCTACCTCA GCCTGGAGCA CTCCCTCTAA    2276

CTCCCCAACG GCTTGGTACT GTACTTGCTG TGACCCCAAC GTGCATTGTC CGGGTTAGGC    2336

ACTGTGAGTT GGAACAGCTC ATGACATCGG TTGAAAGGCC CACCCGGAAA CAGCTAAGCC    2396

AGCTCTTTTG CCAAAGGATT CATGCCGGTT TTCTAATCAA CCTGCTCCCT AGCATTGCCT    2456

GGAAGGAAAG GGTTCAGGAG ACTCCTCAAG AAGCAAGTTC AGTCTCAGGT GCTTGGATGC    2516

CATGCTCACC GATTCCACTG GATATGAACT TGGCAGAGGA GCCTAGTTGT TGCCATGGAG    2576

ACTTAAAGAG CTCAGCACTC TGGAATCAAG ATACTGGACA CTTGGGGCCG ACTTGTTAAG    2636

GCTCTGCAGC ATCAGACTGT AGAGGGGAAG GAACACGTCT GCCCCCTGGT GGCCCGTCCT    2696
```

GGGATGACCT CGGGCCTCCT AGGCAACAAA AGAATGAATT GGAAAGGATG TTCCTGGGTG 2756

TGGCCTAGCT CCTGTGCTTG TGTGGATCCC TAAAGGGTGT GCTAAGGAGC AATTGCACTG 2816

TGTGCTGGAC AGAATTCCTG CTTATAAATG CTTTTTGTTG TTGTTTTGTA CACTGAGCCC 2876

TGGCTGAGCC ACCCCACCCC ACCTCCCATC CCACCTTTAC ACGCCACTCT TGCATGAGAA 2936

CCTGGCTGTC TCCCACTTGT AGCCTGTGGA TGCTGAGGAA ACACCCAGCC AAGTAGACTC 2996

CAGGCTTGCC CCTATCTCCT GCTATGAGTC TGGCCTCCTC ATTGTGTTGT GGGAAGGAGA 3056

CGGGTTCTGT CATCTCGGAA CGCCCACACC GTGGATGTGA ACAATGGCTG TACTAGCTTA 3116

GACCAGCTTA GGGCTCTGCA TATCACAGGA GGGGGAGCAG GGAACAATTT GAGTGCTGAC 3176

CTATAACACA GTTCCTAAAG GATCGGGCAG TCCAGAATCT CCTCCTTCAG TGTGTGTGTG 3236

TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTCCATGTT TGCATGTATG TGTGTGCCAG 3296

TGTGTGGAGG CCCGAGGTTG GCTTTGGGTG TGTTTGATCA CTCTCCAGTT ACTGAGGCGG 3356

GCTCTCATCT GTACCCAGAG CTTGCACATT TTCTAGTCTA ACTTGATTCA GGGATCTCTG 3416

TCTGCCTATG GAGGTGCTCA GGTTACAGGC AGGCTGCCAT ACCTGCCCGA CATTTACATG 3476

AATACTAGAG ATCTGAATTC TGGTCCTCAC ACTTGTATAC CTGCATTTTA TCCACTAAGA 3536

CATCTCTCCA AGGGCTCCCC CTTCCTATTT AATAAGTTAG TTTTGAACTG GCAAGATGGC 3596

TCAGTGGGTA AGGCAGTTTG CGGACAAACC TGATGACCTG AGTTGGATCC CTGACCATAA 3656

GGTAGAAGAG ACCTGATTCC TGCAAGTTGT CCTCTGACCA CCACCCCATA CATGCTTCTG 3716

CATATGTGCA CACATCACAT TCTTGCACAC ACACTCACAT ACCATAAATG TAATAAATTT 3776

TTTTAAATAA ATTGATTTTA TCTTTTAAAA AAAAAAA 3813

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 474 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ala Pro Ala Ala Leu Trp Val Ala Leu Val Phe Glu Leu Gln Leu
-22 -20 -15 -10

Trp Ala Thr Gly His Thr Val Pro Ala Gln Val Val Leu Thr Pro Tyr
-5 1 5 10

Lys Pro Glu Pro Gly Tyr Glu Cys Gln Ile Ser Gln Glu Tyr Tyr Asp
15 20 25

Arg Lys Ala Gln Met Cys Cys Ala Lys Cys Pro Pro Gly Gln Tyr Val
30 35 40

Lys His Phe Cys Asn Lys Thr Ser Asp Thr Val Cys Ala Asp Cys Glu
45 50 55

Ala Ser Met Tyr Thr Gln Val Trp Asn Gln Phe Arg Thr Cys Leu Ser
60 65 70

Cys Ser Ser Ser Cys Thr Thr Asp Gln Val Glu Ile Arg Ala Cys Thr
75 80 85 90

Lys Gln Gln Asn Arg Val Cys Ala Cys Glu Ala Gly Arg Tyr Cys Ala
95 100 105

Leu Lys Thr His Ser Gly Ser Cys Arg Gln Cys Met Arg Leu Ser Lys
110 115 120

Cys Gly Pro Gly Phe Gly Val Ala Ser Ser Arg Ala Pro Asn Gly Asn
125 130 135

Val Leu Cys Lys Ala Cys Ala Pro Gly Thr Phe Ser Asp Thr Thr Ser
140 145 150

Ser Thr Asp Val Cys Arg Pro His Arg Ile Cys Ser Ile Leu Ala Ile
155 160 165 170

Pro Gly Asn Ala Ser Thr Asp Ala Val Cys Ala Pro Glu Ser Pro Thr
175 180 185

Leu Ser Ala Ile Pro Arg Thr Leu Tyr Val Ser Gln Pro Glu Pro Thr
190 195 200

Arg Ser Gln Pro Leu Asp Gln Glu Pro Gly Pro Ser Gln Thr Pro Ser
205 210 215

Ile Leu Thr Ser Leu Gly Ser Thr Pro Ile Ile Glu Gln Ser Thr Lys
220 225 230

Gly Gly Ile Ser Leu Pro Ile Gly Leu Ile Val Gly Val Thr Ser Leu
235 240 245 250

Gly Leu Leu Met Leu Gly Leu Val Asn Cys Ile Ile Leu Val Gln Arg
255 260 265

Lys Lys Lys Pro Ser Cys Leu Gln Arg Asp Ala Lys Val Pro His Val
270 275 280

Pro Asp Glu Lys Ser Gln Asp Ala Val Gly Leu Glu Gln Gln His Leu
285 290 295

Leu Thr Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala
300 305 310

Ser Ala Gly Asp Arg Arg Ala Pro Pro Gly Gly His Pro Gln Ala Arg
315 320 325 330

Val Met Ala Glu Ala Gln Gly Phe Gln Glu Ala Arg Ala Ser Ser Arg
335 340 345

Ile Ser Asp Ser Ser His Gly Ser His Gly Thr His Val Asn Val Thr
350 355 360

Cys Ile Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser
365 370 375

Ser Gln Ala Ser Ala Thr Val Gly Asp Pro Asp Ala Lys Pro Ser Ala
380 385 390

Ser Pro Lys Asp Glu Gln Val Pro Phe Ser Gln Glu Glu Cys Pro Ser
395 400 405 410

Gln Ser Pro Cys Glu Thr Thr Glu Thr Leu Gln Ser His Glu Lys Pro
415 420 425

Leu Pro Leu Gly Val Pro Asp Met Gly Met Lys Pro Ser Gln Ala Gly
430 435 440

Trp Phe Asp Gln Ile Ala Val Lys Val Ala
445 450